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Abstract 
Cyanobacteria have been extensively studied due to their prolific capacity to biosynthesize natural 
products with potent biological activities and fascinating chemistry behind their biosynthesis. 
Bartolosides are a group of halogenated dialkylresorcinols found in certain cyanobacteria that rely 
on the recruitment of fatty acid derivatives from the primary metabolism. Armed with this 
knowledge, we envisioned that this could be harnessed to incorporate terminal alkyne moieties 
into the alkyl chains of bartolosides, generating click chemistry-accessible versions that could be 
used for probing their biological role. To achieve this, we supplemented cultures of a bartoloside 
producing cyanobacterium – Synechocystis salina LEGE 06099 –  with terminal alkyne-containing 
fatty acids. Instead, our experiments led us to detect and later isolate bartoloside esters of the 
supplemented 6-heptynoic acid. We then demonstrated that naturally occurring esterified versions 
of bartolosides could be found in S. salina LEGE 06099 in the absence of fatty acid 
supplementation. Such findings encouraged us to focus our attention on the bartolosides 
biosynthetic gene cluster, brt, particularly the enzyme BrtB which had no ascribed function. 
Through several in vitro assays we established that BrtB is responsible for the esterification of 
bartolosides. BrtB is a novel enzyme that alkylates free fatty acids using secondary alkyl chlorides 
(the bartolosides). It is the second enzyme of its family to be characterized following the Friedel-
Crafts C-alkylating enzyme, CylK. Phylogenetic analysis of these enzymes revealed a series of 
cyanobacterial biosynthetic gene clusters that may represent opportunities for the discovery of 
novel natural products and enzymes.  
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Resumo 
As cianobactérias têm sido extensivamente estudadas devido à sua capacidade prolífica de 
produzir compostos naturais derivados de processos bioquímicos únicos associados à sua 
biossíntese. As bartolosidas são um grupo de dialquilresorcinóis halogenados encontrados em 
certas cianobactérias que dependem do recrutamento de ácidos gordos derivados do 
metabolismo primário. Com isto em mente, previmos que isso poderia ser aproveitado para 
incorporar alcinos terminais nas cadeias alifáticas das bartolosidas, gerando versões acessíveis 
a “click chemistry” que poderiam ser utilizadas para investigar a sua função biológica. Para isso, 
suplementamos as culturas de uma cianobactéria produtora de bartolosidas - Synechocystis 
salina LEGE 06099 - com ácidos gordos contento alcinos terminais. Contudo, as nossas 
experiências levaram à deteção e, posterior, isolamento de ésteres de bartolosides com o ácido 
6-heptinóico suplementado. Em seguida, demonstramos a ocorrência natural de versões 
esterificadas das bartolosidas, encontradas na cultura de S. salina LEGE 06099 sem 
suplementação de ácidos gordos. Estes resultados encorajaram-nos a dedicar nossa atenção no 
“cluster” biossintético das bartolosidas, brt, particularmente na enzima BrtB, inicialmente sem 
função conhecida. Através de vários ensaios in vitro, estabelecemos que a BrtB é responsável 
pela esterificação de bartolosidas. BrtB é uma nova enzima que alquila ácidos gordos livres 
usando as cadeias alifáticas cloradas presentes nas bartolosidas. Esta é a segunda enzima da 
sua família a ser caracterizada após a enzima CylK que catalisa a alquilação de Friedel-Crafts. A 
análise filogenética dessas enzimas revelou uma série de “clusters” biossintéticos 
cianobacterianos que podem representar oportunidades para a descoberta de novos compostos 
e enzimas naturais. 
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I. Introduction 
 Impact of natural products in the biological sciences and industry 
Natural products have impactful roles in our society. With the serendipitous discovery of penicillin 
by Alexander Fleming, 19291, modern natural products research flourished with potential 
applications in several fields, namely drug discovery, nutrition, chemical biology and also in the 
industry.2-3 However, the understanding of what a natural product is may not be clear and 
consistent throughout different scientific areas. From the chemical point of view, a natural product 
can be described as a small molecule derived from a biological source and that is not strictly 
required for the development and viability of the producing organism.2, 4 
From a historical point of view, mankind has always entrusted Nature to supply not only food but 
also ways to improve life quality. Natural products have been used in traditional medicine from 
ancient times, with records of plant-based substances dating 2600 B.C.5 However, secondary 
metabolite chemical diversity and biological importance started to gain more importance after 1817 
with the isolation of morphine from Papaver somniferum by a German pharmacist Friedrich 
Sertuerner.6 Such discovery motivated scientists to pursue plant based compounds capable of 
helping the treatment of a wide spectrum of diseases, for example, the discovery of quinine, a 
promising antimalarial drug from the bark of Cinchona species.7  
Plant derived natural products were undoubtedly fundamental to the improvement of life quality 
throughout the times, but advances in microbiology research stimulated the screening for bioactive 
secondary metabolites from microbial sources. 8 As mentioned above, the discovery (Alexander 
Fleming) and isolation (Howard Florey) of penicillin from the fungus Penicillium notatum triggered 
a massive interest in studying microbial organisms’ secondary metabolism, with a special focus 
on bacteria.9 The huge diversity of bacteria was, by itself, a motivation to seek for bioactive 
compounds that could increase and expand the scientific horizons in terms of chemical and 
structural diversity together with the promising biological and industrial role of bacterial 
metabolites. In fact, even though natural products found in the Plantae kingdom are approximately 
eight times the ones found in the Bacteria kingdom, the relative amount of bacterial bioactive 
secondary metabolites is heavily superior.9-10 Many bioactive compounds obtained from bacterial 
sources present antibacterial properties9-10 (Figure 1), representing 51% of all FDA-approved 
antibacterial natural products obtained from either plants, fungi or bacteria.11 For instance, 
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Actinomycetes, a group of filamentous gram positive bacteria, are responsible for the production 
of almost all antibiotics used in the pharmaceutical industry, with almost 75% of reported bioactive 
compounds being produced by a single genus, Streptomyces.12-13 One of the most significant 
antibiotics with bacterial origin is streptomycin, initially isolated by Albert Schatz and Selman 
Waksman in 1944, which was later introduced in the market as a tuberculosis treatment as result 
of its strong activity against Mycobacterium tuberculosis.14-15 
As discussed above, secondary metabolites were initially studied with the aim to find novel 
compounds, with special consideration to antibacterial and anticancer compounds. However, the 
applications of such diverse and complex natural products goes beyond their direct application to 
the pharmaceutical industry. The fast increase in global population demanded more intense 
farming practices and with that the need for products capable of both protecting the cultivations 
and conserving the produced food.10, 16 Further concern was also related with the handling of 
environmentally friendly compounds due to their low toxicity when compared to other industrial 
chemicals.17 With that in mind, natural products started to gain relevance in these fields and 
secondary metabolite producers started to be screened for potential applications in agricultural 
Figure 1. Major bioactivities of natural products and their distribution throughout 
the different kingdoms of life. Adapted from Chassagne et al. 2019. 
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activities and food industry.16 For instance, natural products have been actively applied as 
pesticides and herbicides as well as food additives and preservatives with the financing dedicated 
to these fields usually rounding 50 billion dollars per year10, 17-18, once again with a special focus 
on bacterial secondary metabolites.19 From the reported and approved natural products used as 
pesticides, avermectin was one of most recognized compounds due to its potent anthelmintic 
activity.20 This secondary metabolite, produced by Streptomyces avermitilis, causes the 
hyperexcitation of invertebrates’ nervous system and effectively paralyzes them, protecting 
plantations from being damaged.16, 21 Secondary metabolites have also been extensively studied 
and employed as food ingredients, as in the application of pigments as natural colorants, which 
can also be derived from microbial sources.22 In some cases, secondary metabolites may be used 
both as food additives to confer specific colors but also as bioactive compounds – the 
cyanobacteria and microalgae-derived scytonemin and astaxantin, respectively, serve as good 
examples due to their anti-inflammatory properties.23-24 
Although natural products unarguably have a clear role in our daily lives, their potential 
applications go beyond their direct use. Advances in interdisciplinary domains, such as chemical 
sciences, have been driven by attempts to mimic the intricate and complex chemistry and 
biosynthesis of natural products.25 The use of enzymes in chemical synthesis (biocatalysis) is 
currently a very promising field of academic and industrial research. Biocatalysis offers several 
advantages for the pharmaceutical industry, for example, due to the economic and environmental 
benefits over traditional “non-green processes”.26 Enzymes allow the synthesis of different 
products due to their regio- and stereo- selectivity without the need for protection steps as in 
organic synthesis.26-27  
The use of biocatalysis over traditional chemical catalysts also allows the expansion of organic 
synthesis’ toolbox with the use of several reactions such as oxidations, reductions, halogenations 
among other, with a special focus on alkylation reactions. For instance, chemical synthesis 
reactions that require either O-alkylation, C-alkylation and N-alkylation are time-consuming and 
are not economical and environmentally viable due to the use of toxic alkylating agents.27 A great 
example of enzymatic catalysts are methyltransferases, a widespread group of enzymes involved 
in the transfer of methyl groups, which can be green alternatives for Friedel-Crafts alkylations 
(figure 2).28-29 The catalytic mechanism of enzymatic oxidations are also of great interest to the 
pharmaceutical industry since they avoid undesired side-products due to their high 
stereoselectivity.30 However, enzymatic catalysis is not adapted to industrial processes leading to 
the necessity for advancements in protein engineering with regard to the reaction thermodynamics 
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and specificity of the enzymatic reactions.31 Additionally, innovative methodologies that improve 
the biocatalysts performance have also been explored, for example in the scale up of Bayer-
Villiger oxidations through the use of bioreactors and resin based methodologies (figure 2).30, 32 
This reaction is performed by flavin-dependent monooxygenases, which are usually related with 
natural product biosynthesis and can be adapted to organic synthesis and in prodrug activation.33-
34 Besides, studying proteins and enzymes allows to better understand how reactions are carried 
in terms of substrate affinity to active centers as well as substrate interactions and enzymatic 
folding. 
 Cyanobacteria are prolific natural product producers 
Terrestrial bacteria are the most well-known source of bioactive metabolites, but extensive 
exploration programmes led to a decrease in the number of new natural products discovered from 
these sources each year.35 On the other hand, the development of efficient strategies and 
technologies for marine sampling allowed to expand the secondary metabolite discovery to the 
oceans due to the high biological and chemical diversity associated.36-37 
Cyanobacteria are widespread photosynthetic gram-negative prokaryotes that can be found in 
different environments, such as freshwater and marine ecosystems as well as in extreme 
Figure 2. Examples of enzymatic reactions used in natural product biosynthesis. a) Methyltransferase NovO performs an 
enzymatic Friedel-Crafts alkylation, using S-Adenosyl methionine (SAM) as a cofactor, to introduce a methyl moiety in aromatic 
substrates. 29 b) Cyclohexanone monooxygenase performs Bayer-Villiger oxidations.33 Adapted from Tengg et al. 2016 and 
Hilker et al. 2005. 
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habitats.38-39 They have had an important role in the production of oxygen dating at least 2.3 billion 
years ago, which make these organisms one of the most ancient and diverse groups of organisms 
on our planet. 40-41 Cyanobacteria are also unique among bacteria since some species are capable 
of cell differentiation into structures called heterocysts and akinetes.41 The ability of 
compartmentalization allows these microorganisms to fix nitrogen, in the heterocysts, and survive 
under extreme conditions (e.g. light deprivation) by entering a vegetative-like status through the 
specialized cells akynetes.41  
Although they are commonly recognized as oxygen producing microorganisms, cyanobacteria are 
also a prolific source of secondary metabolites. 38-39, 42 Richard Moore was a pioneer in this field 
with his group’s work in cyanobacterial derived compounds and was responsible for the discovery 
of dozens of cyanobacterial secondary metabolites, such as majusculamides A and B43, 
oscillatoxins or debromoaplysiatoxin.44-46 There are many applications for cyanobacterial 
compounds due to their varied biological properties such as UV protection conferred by the 
scytonemins47 or anticancer activity, e.g. dolastatin 10, the pharmacophore of the anticancer drug 
brentuximab vedotin.48-50 However, the question of what distinguishes cyanobacteria from other 
secondary metabolite producers arises. The high chemical diversity of cyanobacteria is in fact one 
of the reasons that make such organisms great targets for natural product discovery.38-39, 51 The 
vast and unique mechanisms involved in the biosynthesis of cyanobacterial secondary 
metabolites allow these microorganisms to generate varied compounds that are of interest to 
chemists and biologist alike.  
The secondary metabolite production relies on a biosynthetic machinery consisting of a 
contiguous arrangement of a set of genes defined as biosynthetic gene clusters (BGCs).52-53 
Bacterial genes codifying for secondary metabolites are physically clustered while in plants the 
biosynthesis of natural products does not follow this assembly line, which contributed to the focus 
on bacterial genomes.54 The rationale behind BGCs is that the biosynthetical pathway involves 
the interaction of each enzyme of the cluster with substrates to promote the “brick by brick” 
construction of the resulting secondary metabolite (figure 3). Additionally, biosynthetic gene 
clusters can include enzymes capable of performing halogenation reactions (e.g. chlorine and 
bromine) as well as other mechanistically interesting reactions that enable the production of a 
broad range of metabolites with different chemical moieties.55  
Apart from the compounds generally present in other organisms such as terpenes and 
polysaccharides, these photosynthetic microorganisms produce metabolites that may enclosure 
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chemically diverse structures that range from lipid- to amino acid-based skeletons., among 
others.38, 51, 56 In fact, cyanobacterial metabolites can be classified according to their chemical 
structural and divided into 10 classes including alkaloids, polyketides and peptides, as well as 
hybrids thereof.38 Most of the metabolites produced by cyanobacteria are peptides38 that are 
mainly derived from non-ribosomal peptides synthetases (NRPS) or ribossomally-produced and 
post-translationally modified peptide (RiPP) systems. NRPs are synthesized by the action of 
several enzymes encoded in their respective BGCs, without the involvement of ribosomal RNA as 
in the usually seen peptides.56-57 On the other hand, RiPPs biosynthesis relies on a ribosomally 
generated peptide containing recognition sequences that will later promote post-translationally 
modifications, such as cyclization, yielding the final natural product (e.g. sphaerocyclamide).58-59 
Additional secondary metabolites are the fatty acid-based compounds called polyketides (PKs), 
e.g. oscillatoxins45. Their biosynthesis relies on the action of modular systems consisting on the 
elongation of activated fatty acids and posterior modifications resulting in a broad structural 
diversity.60-61 
Figure 3. Examples of structural and chemical diversity of cyanobacterial secondary metabolites. a) depicted is scheme of a partial 
biosynthetic gene cluster. b) Dolastatin 10 is a lipopeptide derived from marine cyanobacterium Symploca sp. that has potent 
anticancer activity.58Oscillatoxin A is a toxic metabolite derived from PKS systems46. Sphaerocyclamide is a RiPP found in the 
cyanobacterium Sphaerospermopsis sp. LEGE 00249.60  
FCUP 
A novel biocatalytic esterification involved in the biosynthesis of branched bartolosides 7 
In addition, cyanobacteria are capable of producing remarkable compounds such as lipopeptides, 
which contain lipid chains bound to peptide moieties, e.g. the previously mentioned dolastatin 10.62  
The cyanobacterial chemical diversity encourages the discovery of natural products not only for 
the novelty of the enzymatic chemistry behind their biosynthesis but also for the opportunity to 
discover new potent activities. 
 Approaches for natural product and drug discovery  
The discovery of penicillin caused the emergence of the Golden Age of natural products where 
the main focus was drug discovery. This generated a need for developing efficient approaches 
capable of providing a high rate of natural product discovery that could be used in the industry. 
During these years, the application of bio-guided drug discovery was the main and only source of 
potential candidates due to the simple assays and methodologies that could be applied.63 Put 
simply, target cells were exposed to microbial extracts and the phenotype of the assay would 
dictate the compounds activity and determine the need for further isolation efforts.63 However, 
such methodologies soon started to be ineffective due to the time consuming and expensive 
methodologies applied, which led to the need for high throughput screening approaches.63-65 
When the scientists started to focus on the chemical diversity of natural products techniques such 
as mass spectrometry (MS) and nuclear magnetic resonance (NMR) were extensively used and 
allowed faster dereplication processes and secondary metabolite discovery.66 In fact, the 
applicability of combinatorial bio-guided and mass spectrometry approaches is still used for the 
discovery of natural products.e.g.67  
Nevertheless, with the fast development in DNA sequencing technologies68 the natural products 
area witnessed a resurgence of interest relying on genomic and bioinformatic approaches. For 
instance, metagenomics allowed the discovery of an unprecedented number of compounds from 
uncultured microorganisms.69 Additionally, genome mining approaches allowed the fast expansion 
in knowledge of both biosynthetic gene cluster architechture and natural product chemistry in the 
beginning of the 21st century.70 However, predicting the end-product of a gene cluster can be 
sometimes challenging. Such problem could be addressed, for example, through the use of 
heterologous systems: entire BGC can be cloned into suitable heterologous hosts (e.g. 
Streptomyces sp.) to access the secondary metabolite derived from the gene cluster inserted.e.g.71-
72 In the case of cyanobacterial secondary metabolites such bioinformatic approaches have been 
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extensively used for the characterization of PKS and NRPS derived compounds. 73-74 These 
strategies have allowed the discovery of a huge variety of cyanobacterial natural products but 
such methodologies are still non-universal, can be time consuming or even discouraging.  
One other subject of natural products research is the study of their mode of action, in particular, 
regarding their ecological or pharmacological relevance. Achieving this, however, is not trivial. 
Click chemistry has emerged as a powerful set of biorthogonal reactions (i.e. chemical reactions 
occurring in living systems without affecting their biological processes75) that are acknowledged 
for their fast and simple procedures with a wide-range of applications in chemical biology, e.g. 
deciphering the mode of action of a natural product.76-77 One of the most common approaches 
relies on heterocycle formation between azides and terminal alkyne moieties through a copper-
catalyzed Huisgen ,3-dipolar cycloaddition (figure 4).78 Click chemistry advancements have 
allowed the creation of studies based in bio-conjugation of functionalities of interest to the azide, 
later generating a tagged version of the desired compound which is suitable for both in vivo and 
in vitro studies.77, 79-80 
 Bartolosides, a group of cyanobacterial dialkylresorcinols 
Bartolosides are a recently discovered and unprecedented group of cyanobacterial secondary 
metabolites present in some cyanobacteria with uncommon features such as a chlorinated 
dialkylresorcinol (DAR) core or C-glysosyl moieties.81-82 Non-halogenated DAR scaffolds are 
somewhat common in other bacteria but only a few DAR compounds have been discovered from 
cyanobacteria, e.g. paracyclophanes, microcarbonin A and nostocyclyne A. 83-86 
Bartolosides can be divided into two groups according to their structure: i) monoglycosylated 
versions, containing an O-linked β-D-xylosyl moiety and ii) diglycosylated versions featuring an O-
linked α-L-rhamnose and a C-linked xylose while additional differences consist in the alkyl chain 
length that can range from 11 to 15 carbons.81-82 Bartolosides A-K have been discovered and 
Figure 4. Click chemistry using azides and terminal alkynes. For example, terminal alkyne labelled natural products (NP) react with 
azides to form a heterocycle through a copper-catalyzed Huisgen 1,3-dipolar cycloaddition. Azides can be tagged with several moieties 
such as biotin and fluorophores. 
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isolated from the coccoid cyanobacterium Synechocystis salina LEGE 06155 and Synechocystis 
salina LEGE 06099 as well as from the filamentous Nodosilinea sp. LEGE 06102. 
The bartolosides biosynthetic gene cluster (brt) (Figure 6) encodes two enzymes essential for the 
dialkylresorcinol formation (DAR). The ketosynthase BrtD performs the condensation between two 
fatty acyl thioester derivatives leading to the ring formation while the flavin-dependent aromatase 
BrtC finalizes the resorcinol formation.82 Additional genes brtGHI encoded in the brt cluster are 
involved in the glycolipid export while brtAEF encode glycosyltransferases. Halogenation of the 
alkyl chains in the bartolosides is predicted to be performed by BrtJ since some of its homologs 
(CylC, ColD/ColE) have been found in cyanobacterial biosynthetic gene cluster encoding for 
halogenated secondary metabolites, cylindrocyclophanes and columbamides.87-88 Previous 
bioinformatic analysis also supports that this enzyme belongs to a class of dimetal halogenases 
acting on unactivated carbons.81-82  
Figure 5. Bartolosides chemical structures enclose several chlorinations, different alkyl chain lengths and can be mono- or 
diglycosylated.  
Bartoloside R1 R2 R3 R4 
A (1) Cl H H C3H7 
E H H Cl CH3 
F Cl H H C4H9 
G (2) H H H C3H7 
H Cl H H C5H11 
I Cl Cl H C3H7 
J H H H CH3 
K Cl H H C2H5 
 
Bartoloside R5 R6 
B Cl H 
C H H 
D Cl H 
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An additional enzyme – BrtB – is encoded in the brt cluster. Phylogenetic analysis indicates that 
BrtB and CylK - an enzyme that participates in paracyclophane biosynthesis – are homologs.89 
The paracyclophanes are cyanobacterial natural products that contain aryl-alkyl linkages in their 
core structure, however, the biocatalytic mechanisms behind paracyclophane assembly were only 
recently clarified, in particular the function of CylK.87, 89 Through several in vitro assays this enzyme 
(annotated as hemolysin-type calcium-binding protein) was shown to be responsible for the 
Figure 6. Biosynthesis of bartolosides and cylindrocyclophanes. a) Bartolosides biosynthetic gene cluster, brt, from S. salina 
LEGE 06099 and S. salina LEGE 061155 with annotated gene functions. b) proposed mechanism of dialkylresorcinol formation in 
bartolosides B-D. Leão et al. 2015.c) CylK catalyzes the paracyclophane formation in the cylindrocyclophanes.  
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paracyclophane formation through a Friedel-Crafts alkylation between the chlorinated chains of 
the intermediates and the resorcinol ring through a SN2 nucleophilic substitution (Figure 6c).89-90 
Despite its homology with CylK, the function of BrtB has remained unclear. The reasons behind 
this are that a CylK-like mechanism is not necessary for the biosynthesis of the known bartolosides 
and that CylK requires a free C-2 position in the alkylresorcinol, which is unavailable in the 
bartolosides.  
 
Objective: The biosynthesis of the dialkylresorcinol skeleton in the bartolosides involved 
recruitment of fatty acids derivatives from primary metabolism. We envisioned that this could be 
exploited to incorporate terminal alkyne moieties into bartolosides and generate click-chemistry 
accessible versions of these secondary metabolites for probing their biological role. However, 
while attempting this we encountered unexpected results that led us to diverge from this initial aim 
and focus on the: 
 Isolation of novel bartolosides from S. salina LEGE 06099; 
 Biosynthesis of the novel bartolosides in S. salina LEGE 06099. 
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II. Results and Discussion 
 Incorporation of terminal alkyne-containing fatty acids into bartolosides  
As previously mentioned, the biosynthesis of bartolosides involves the recruitment of fatty acid 
derivatives from primary metabolism to assemble the dialkylresorcinol skeleton. We hypothesized 
that this could be exploited to incorporate terminal alkyne moieties into these natural products, 
making them accessible for click chemistry experiments to gain insights in their biological role.  
In order to understand if cyanobacteria could incorporate the desired terminal alkynes we initially 
assessed whether they could be toxic to the cyanobacterial cells. To this end, we supplemented 
the bartoloside producer Synechocystis salina LEGE 06099, with both 5-hexynoic and 6-heptynoic 
acids at three different concentrations (5, 10 and 50 mg L-1). The OD750nm was measured in a 96-
well plate in a microplate reader (Synergy HT, BioTek) at day 0 (day of supplementation) and 
every 2 days until reaching the 30-day period. 
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5 mg/L 10 mg/L 50 mg/LFigure 7. S. salina LEGE 06099 growth over 3  days after exposing the culture to both 5-hexynoic 
(top) and 6-heptynoic acid (bottom). 
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We observed that supplementation with both acids did not affect the normal growth of S. salina 
LEGE 06099 since they presented the normal growth curve tending to the stationary phase after 
20 days, approximately. Additionally, the highest concentration applied (50 mg/L) was still soluble 
in water and did not precipitate. These allowed us to proceed with the experiments and analyze 
the incorporation of the terminal alkyne-containing fatty acids into the cells. 
After harvesting the cells and performing the extraction of organic compounds with a mixture of 
MeOH/CH2Cl2 the samples were analyzed by LC-HRESIMS. Since the target compounds 
(bartoloside derivatives) have long aliphatic chains we adapted the LC method to be able to 
observe highly non-polar species (see “Materials and Methods” section). The output analysis 
revealed a massive depletion of the major metabolite bartoloside A (1) levels as well as those of 
several other analogues (figure 9). However, when searching for the m/z values corresponding to 
terminal-alkyne versions of bartoloside A and other major metabolites we did not detect any ions 
compatible with these structures. Bartoloside A (1) is one of the most abundant secondary 
metabolites in this strain, representing around 0.6% dry weight81, which means that the feeding 
experiment performed could either have affected its biosynthesis or have been incorporated in an 
unexpected region. 
 
Figure 8. Supplementation of terminal alkyne-containing fatty acids was expected to lead to the incorporation of terminal 
alkyne moieties into the alkyl chains of bartolosides produced by S. salina LEGE 06099. 
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In order to understand the reason behind bartolosides depletion, we sought to find new masses 
that were only present in the samples corresponding to supplemented cultures. Further analysis 
of the obtained chromatograms revealed a very different profile between samples and led to the 
detection of several peaks that were highly abundant in the cultures exposed to the fatty acids but 
were absent in the controls (figure 10). We verified that these ions were consistent with the 
incorporation of one or two units of the supplemented fatty acids with the concomitant loss of one 
or both Cl atoms in bartolosides A (1) and G (2) (most abundant metabolites), respectively. 
In order to support our hypothesis, we performed fragmentation of some of the new abundant ions 
through LC-HRESIMS/MS analysis of the crude extracts (figures 11 and 12). The data showed 
fragments corresponding to the intact alkyne precursors or their neutral loss in the bartolosides 
core structure. This suggested that the detected peaks could correlate with esterified versions of 
bartolosides 1 and 2 with 5-hexynoate and 6-heptynoate.  
Figure 9. Depletion of bartolosides levels in S. salina LEGE 06099 supplemented with fatty acids. Analysis was carried by LC-
HRESIMS of the crude extracts obtained and presented are the extracted ion chromatograms (EICs) of the m/z correspondent 
to the [M-H]- ions of bartolosides.  
FCUP 
A novel biocatalytic esterification involved in the biosynthesis of branched bartolosides 15 
 
Figure 10. Total Ion Chromatograms obtained from LC-HRESIMS analysis. Supplementation 
with 5-hexynoic and 6-heptynoic acids led to the formation of new abundant masses absent in 
the control. Additionally, bartoloside A level was depleted in the exposed cultures.  
Figure 11. Formation of bartoloside A and G esters upon supplementation of S. salina LEGE 06099 with 6-
heptynoic acid. Here we present the proposed chemical structures and respective annotated LC-
HRESIMS/MS data for compounds 3 and 4. 
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 Isolation of branched bartolosides formed under supplementation 
The previously performed experiments showed that supplementation with 5-hexynoic and 6-
heptynoic acids did not generate terminal alkyne moieties in the DAR moiety of the bartolosides 
but instead led to the formation of new compounds. To unambiguously establish the chemical 
structure of the newly observed metabolites we sought to isolate and purify the major metabolites 
found under supplementation with fatty acids. 
To fulfill our objective, we performed a 20 L cultivation of S. salina LEGE 06099 under 
supplementation with 6-heptynoic acid at a concentration of 50 mg L-1 in order to try to obtain a 
Figure 12. Formation of bartoloside A and G esters upon supplementation of S. salina LEGE 06099 with 5-hexynoic acid. Here we 
present the proposed chemical structures and respective annotated LC-HRESIMS/MS data for compounds s1a/s1b, s2 and s3. 
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sufficient amount of compound for structure elucidation. The harvested freeze-dried biomass (5.6 
g, d. w.) was extracted by repeated percolation using a mixture of CH2Cl2/MeOH (see “Materials 
and Methods” section) resulting in a crude extract of 754.6 mg. Subsequent fractionation was 
achieved by normal phase flash chromatography using a gradient of increased polarity from 
hexane to ethyl acetate (EtOAc) to methanol (MeOH). The fractionation originated eight fractions 
(1-8) with similar TLC (thin layer chromatography) profiles. Fractions 4 (13.5 mg), 5 (102.2 mg) 
and 6 (14.5 mg) eluting with a 2:3 mixture of EtOAc/hexane were analyzed by LC-HRESIMS and 
indicated the presence of the desired m/z corresponding to the hypothetical branched bartolosides 
A and G (m/z 839.5678 [M-H]- and 715.5154 [M-H]-, respectively). At this stage, depending on the 
relative abundance of each compound, we could have pooled the fractions together but 
considering that both compounds were mostly present in fraction 5 (figure 13) we decided to only 
go forward with this sample for further fractionation. 
The isolation of the desired metabolites involved a new chromatographic step using a reverse-
phase semipreparative HPLC which allows a more efficient peak collection since we can track the 
separation progress in real time with the help of a PDA (photodiode array) detector. The HPLC 
program was adapted to allow the proper resolution of all peaks. Initially we tested an isocratic 
gradient of 80% acetonitrile in water during 25 minutes but peak separation was insufficient. After 
increasing the acetonitrile concentration to 90% we verified a more efficient separation with the 
Figure 13. Extracted Ion Chromatograms (EICs) of m/z 839.5678 [M-H]- (compound 3) and m/z 715.5154 [M-H]- (compound 4) 
from the LC-HRESIMS of fractions obtained from the flash chromatography performed for the isolation of 3 and 4. 
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advantage of a faster fractionation since the compounds were eluting faster due to the decreased 
polarity of the mixture. Finally, we decided to use an isocratic gradient of 92% acetonitrile in water 
during 25 minutes followed by a washing step with 100% acetonitrile (see “Materials and Methods” 
section), affording 10 subfractions. All subfractions were submitted to 1H NMR to evaluate their 
composition and purity. Fraction 5.6 (48.0 mg, figure 14), eluting at 13.5-15.0 minutes, was 
spectroscopically pure (> 95%, 1H NMR) and showed characteristic signals of bartolosides 
regarding resorcinol and xylosyl protons.81-82 Additionally, fraction 5.10 (4.3 mg, figure 14), with a 
retention time of 24.0-25.0 minutes, was also pure and presented a similar 1H NMR profile to the 
subfraction 5.6 and consequently to the bartolosides. 
 Structural elucidation of esterified bartolosides 3 and 4 
The 1H NMR analysis of both 5.6 and 5.10 subfractions indicated that they were suitable for further 
structural elucidation. Therefore, both samples were submitted to 1D 13C NMR and 2D NMR 
(HSQC, HMBC and COSY) as well as HRESIMS/MS analysis in order to unequivocally establish 
their chemical identity.  
bartoloside A-17,29-diyl bis(hept-6-ynoate) (3)  
HRESIMS analysis of compound 3 (isolated as an orange oil) showed a [M-H]- peak at m/z 
839.5685, compatible with a molecular formula of C50H80O10 (calculated for C50H79O10-, m/z 
839.56867) and 11 degrees of unsaturation. The 1H and 13C NMR spectra showed typical 
bartoloside resonances, namely for the aromatic ring (δC 155.8, 154.6, 141.9, 116.3, 110.4 and 
Figure 14. Reverse phase HPLC chromatogram (a) and PDA heat map spectra (b) of derived from the semipreparative 
chromatography of fraction 5 performed for the isolation of compounds 3 and 4. 
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107.8) and xylosyl (δC 101.4, 72.6, 74.9, 69.7 and 64.5) (annex table 1). Characteristic resonances 
for two ester/acid carbonyls (δC 174.1 and 173.9) and two alkyne moities (δC 68.8, δH 1.95) were 
also observed. The HRESIMS derived molecular formula and isotope pattern of 3 dictated the 
absence of halogens in the molecule. The molecular formula had an additional C14H18O4 when 
compared to the major bartoloside 1 produced by S. salina LEGE 06099 (bartoloside A) consistent 
with the incorporation of two 6-heptynoic acid moieties. This initial analysis strongly suggested 
that compound 3 could correspond to a bartoloside derivative where the chlorinated positions in 1 
were substituted by the supplemented 6-heptynoic acid. To obtain further insights regarding the 
structure of 3, we performed 2D NMR experiments (HSQC, HMBC, COSY). Correlational data for 
the glycosylated dialkylresorcinol moiety were highly similar to those of the bartolosides and it was 
also possible to deduce the structures of two intact 6-heptynoate spin systems from COSY and 
HMBC (figure 15). Notably, two conspicuous protons resonating at δH 4.87 (H-17 and H-29) in 3 
are not found in any of the previously reported bartolosides. Each of these protons was positioned 
in the middle of an alkyl chain (figure 15, annex table 1) and showed HMBC correlations to the 
carbonyls C-1’ (δC 174.1) and C-1’’ (δC 173.9). Strong deshielding indicated that these were 
oxymethine protons and established the directionality of the ester linkages. HRESIMS/MS data, 
which show fragments corresponding to 6-heptynoate (m/z 125.05 [M-H]-, figure 11) are in 
accordance with this observation. Additionally, the resonances for the chlorinated carbons in 
bartoloside A (δC 64.9, δH 4.01)81-82 are not present in 3, further implying ester linkages in positions 
17 and 29. While it was not possible to fully connect the oxymethines to the dialkylresorcinol rings, 
the HRESIMS/MS data of in-source fragments of 3 (figure 16) matches the data for bartoloside A 
(1) and other bartolosides in our previous structural elucidation efforts.81-82 As such, we propose 
that the esterified positions in 3 correspond to the chlorinated positions in 1. 
Optical rotation, infrared (IR) and ultraviolet (UV) fingerprint: 
[α] 25D -5.0 (c 0.60, MeOH); IR (thin film) ʋmax 3398, 3308, 2923, 2857, 1726, 1703, 1590, 1428, 
1052, 1033, 1017, 627 cm-1. UV (MeOH) λmax (log ε) 217 (3.2), 221 (3.2), 273 (3.0). 
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Figure 15. Key HMBC and COSY correlations of bartoloside A-17,29-diyl bis(hept-6-ynoate) (3)  
Figure 16. HRESIMS/MS spectra for the in-source (collision energy of 90 eV) generated fragment of 3 providing the required 
confirmation and validation of the chemical structure of compound 3. 
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bartoloside G-17-yl hept-6-ynoate (4) 
HRESIMS data of compound 4 (isolated as a light orange oil) showed a prominent peak at m/z 
715.5161 [M-H]- which was compatible with a molecular formula of C43H72O8 (calculated for 
C43H71O8-, m/z 715.5162) and 8 degrees of unsaturation. The 1H and 13C NMR data (annex table 
2) were highly similar to those from compound 3, notably featuring a carbonyl resonance (δC 
174.1) and an alkyne moiety signal (δC 68.8, δH 1.95). Additionally, the typical bartoloside 
resonances for the aromatic ring (δC 155.7, 154.3, 142.5, 116.1, 110.4, 108.1) and xylosyl group 
(δC 101.4, 72.6, 74.9, 69.7 and 64.5) were present. The HRESIMS-derived molecular formula and 
isotope pattern of 4 indicated the absence of halogens in the molecule and an additional C7H9O2 
when compared to another bartoloside produced by S. salina LEGE 06099 (bartoloside G, 2). This 
would be consistent with 4 resulting from the incorporation of one 6-heptynoic acid moiety into 2. 
Two-dimensional NMR experiments (HSQC, HMBC and COSY) showed the presence of an intact 
6-heptynoate-derived spin system from COSY and HMBC correlations (figure 17). The HMBC 
correlations for H-17 (δH 4.88) with C-1’ (δC 174.1) indicated an identical ester linkage to that of 3, 
at the C-17 (δC 74.7) position (figure 17). In line with these observations, the HRESIMS/MS data 
for 4 showed a 6-heptynoate-derived fragment (m/z 125.05 [M-H]-, figure 11). By isolating and 
carrying out HRESIMS/MS analysis on an in-source fragment of 4, we obtained diagnostic 
fragments indicating a fully aliphatic alkyl chain with 13 carbons (m/z 249.22 and m/z 291.23, 
figure 18), as well as fragments consistent with an alcohol group in the C12 alkyl chain (e.g. m/z 
225.18 and m/z 319.23, figure 18). We thus propose that metabolite 4 is a derivative of the 
naturally occurring 2, in which the chlorinated position is substituted by a 6-heptynoate moiety. 
Optical rotation, infrared (IR) and ultraviolet (UV) fingerprint: 
[α] 25D -4.6 (c 0.65, MeOH); IR (thin film) ʋmax 3410, 3313, 2923, 2855, 1731, 1704, 1590, 1428, 
1054, 1033, 1014, 627 cm-1; UV (MeOH) λmax (log ε) 216 (3.1), 221 (3.1), 273 (2.8). 
 
Figure 17. Key HMBC and COSY correlations of bartoloside G-17-yl hept-6-ynoate (4). 
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 Incorporation of additional substrates into the bartolosides 
We hypothesized whether additional substrates could be incorporated in the same fashion as the 
terminal alkyne-containing fatty acids supplemented. With this in mind, we set out to investigate 
which type of substrates could be incorporated in the bartolosides alkyl halide chains. 
The previously used S. salina LEGE 06099 strain was exposed to several substrates containing 
not only carboxylate moieties (7-bromoheptanoic, trans-3-hexenedioic, butyric, caprylic, lauric and 
palmitic acids) but also other related nucleophiles commonly used in organic synthesis 
(hexylalcohol and hexanamide). After supplementing the cultures, the cells were harvested, 
extracted as carefully described in the “Materials and Methods” section and analyzed by LC-
HRESIMS. As expected, the results showed the formation of corresponding mono- and diesters 
of both bartoloside A (1) and G (2) with the fatty acids supplemented (figure 19). Since trans-3-
hexenedioic acid contains two carboxylate moieties we hypothesized that the branching could 
occur between two bartolosides or even inside the same molecule through the esterification of 
both alkyl halide chains to the same substrate. However, we could not detect any ion that could 
Figure 18. HRESIMS/MS spectra for the in-source (collision energy of 65 eV) generated fragment of 4 providing the required 
confirmation and validation of the chemical structure of compound 4. 
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correlate with branched versions of bartoloside A and G with hexylalcohol, hexanamide nor trans-
3-hexenedioic indicating selectivity towards fatty acids. Overall, our results show that exogenously 
provided fatty acids are converted in vivo into esterified versions of bartolosides by S. salina LEGE 
06099. 
Figure 19. Bartoloside esters formed in S. salina LEGE 06099 cells upon supplementation with different fatty acids commonly present 
in bacteria and with the halogenated fatty acid 7-bromoheptanoate. LC-HRESIMS of extracted ion chromatograms (EICs) of [M-
H+HCOOH]- adducts of the proposed bartoloside A esters (a) and bartoloside G esters (b). Controls without supplementation are 
depicted in the left panel and supplemented cultures in the right panel.  
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Interestingly, while analyzing the LC-HRESIMS data of our non-supplemented controls we verified 
the presence of two abundant compounds with m/z values and retention times consistent with 
both bartoloside A monopalmitate (5a/5b) and bartoloside G palmitate (6). Such findings led us to 
hypothesize that esterified bartolosides occur naturally in the cyanobacteria and not only while 
under supplementation with exogenous fatty acids. Therefore, we set out to investigate whether 
the detected species was in fact the branched version of bartoloside A monopalmitate (5a/5b). 
 Detection of naturally occurring bartoloside esters 
The previously obtained LC-HRESIMS results of the control samples presented in figure 18 
directed us to search for the naturally occurring bartoloside A monopalmitate (5a/5b) ester (m/z 
879.6486 [M-H]-). Further analysis of the CH2Cl2/MeOH (2:1) cellular extract of S. salina LEGE 
06099 without supplementation used in the chapter revealed the presence of a m/z consistent 
with the diesterified version of bartoloside A with palmitic acid (7, m/z 1099.9177 [M-H]-). The 
higher retention time corroborated with the hypothetical structure due to the putative compound’s 
lower polarity owing to the four alkyl chains.  
With these data in our hands we decided to perform the mass fragmentation of the detected ions 
(m/z 879.6486 [M-H]- and 1099.9177 [M-H]-). The LC-HRESIMS/MS data revealed the presence 
of intact fragments of palmitic acid (m/z 255.2330 [M-H]-) as well as fragments corresponding to 
the previously presented data of the bartoloside A core (figure 20). Fragmentation of the 
hypothetical bartoloside G palmitate (6, m/z 845.6876 [M-H]-) also revealed the presence of 
palmitic acid and bartoloside G fragments, without a chlorine atom, in line with what had been 
observed for the previously isolated compound 4.  
Knowing this, we extensively examined the LC-HRESIMS data for additional esterified versions of 
bartolosides A and G with fatty acids known to be present in cyanobacterial cells.91 This revealed 
20 additional peaks matching with m/z of branched versions of 1 and 2 with fatty acids with varying 
chain length and saturation, which were then analyzed by LC-HRESIMS/MS to confirm the 
presence of corresponding fragments (figure 21, annex figures 1 and 2 ). Putative bartoloside A 
and G esters 5a/5b and 6, respectively, seem to be the most abundant ones as verified by the 
integration of the corresponding peak area (figure 22). 
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Figure 20. Detection and HRESIMS/MS based structural assignment of naturally occurring bartoloside A and G esters of palmitate in 
S. salina LEGE 06099. a) Annotated MS/MS fragments for the structures of bartoloside A mono- (5a/5b) and diester (7) and bartoloside 
G palmitate (6). Depicted are the extracted Ion Chromatograms (EICs) for the [M-H+HCOOH]- ions and MS/MS spectra for the [M-H]-
species of detected bartoloside A esters 5a/5b and 7 (b and c, respectively) as well as bartoloside G ester 6 (d). 
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Figure 21. Detection and HRESIMS/MS based structural assignment of naturally occurring bartoloside esters produced by S. salina 
LEGE06099. a) Annotated MS/MS fragments for the structures of bartoloside A and G esters. b-d) Extracted Ion Chromatograms 
(EICs) for the [M-H+HCOOH]- ion and MS/MS spectra for the [M-H]- specie of some of the detected naturally occurring bartoloside A 
esters. e-g) Extracted Ion Chromatograms (EICs) for the [M-H+HCOOH]- ion and MS/MS spectra for the [M-H]- specie of some 
detected naturally occurring esterified bartoloside G.  
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Even though S. salina LEGE 06099 produces other bartolosides we could not detect any peaks 
corresponding to hypothetical esterified versions of such metabolites due to their low abundance 
in the used strain. 81 On the other hand, proving that the detected peaks were indeed bartoloside 
esters required purification and structure elucidation. 
 Isolation of bartoloside A monoester 5a 
To undoubtedly establish that the LC-HRESIMS detected compounds were indeed branched 
versions of bartolosides we cultivated 20 L of S. salina LEGE 06099 without the supplementation 
of exogenous fatty acids. After extracting the organic compounds from the freeze-dried biomass 
(574.31 mg d.w. crude extract) using a mixture of CH2/Cl2:MeOH (2:1) we performed another flash 
chromatography to fractionate our sample (see “Materials and Methods” section).  
At this point, we had to adapt the solvent concentration since our target compounds are more 
apolar due to their long aliphatic chains. Since we used a normal phase chromatography and 
started with apolar solvents (hexane) our compounds were predicted to have eluted earlier than 
compounds 3 and 4. Therefore, we tried to extend the separation using higher volumes of the 
more apolar mixtures (until 40% EtOAc, 60% hexane). The derived samples were pooled 
according to their TLC profiles originating 23 fractions (1-23) and analyzed by LC-HRESIMS. The 
derived data showed a very weak separation of compounds when compared to the flash 
chromatography performed in the isolation of 3 and 4 since the target compound (m/z 879.6486 
[M-H]-) had eluted throughout several fractions. Fraction 15 (18.81 mg) contained the highest 
relative abundance of the desired peak (putative bartoloside A monopalmitate 5a/5b, m/z 
Figure 22. Relative abundance of naturally occurring bartoloside esters found in S. salina LEGE06099 cells. 
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879.6486 [M-H]-)and was selected for further fractionation through semipreparative reverse phase 
HPLC (figure 23).  
Since we had previously applied a concentration of 92% acetonitrile in water for the isolation of 
compounds 3 and 4 we decided to try and use a higher concentration of acetonitrile (99%) due to 
the non-polar nature of the target modified bartoloside 5a/5b. However, this percentage was not 
sufficient to cause the elution of all compounds present in fraction 15 under 120 minutes (figure 
24a). Therefore, we decided to try methanol for the mobile phase, which, although more polar 
than acetonitrile, is known to be more efficient in eluting compounds when applied in high 
proportion in C18 columns.92 In fact, after adjusting the methanol concentration to an isocratic 
gradient of 98% MeOH in water we obtained a good separation in under 60 minutes (figure 24b). 
From the collected 11 peaks, subfraction 15.7 (retention time 32.1-34.5 minutes) contained one 
of the major peaks and likely the target species with m/z 879.6486 [M-H]-. To validate this, we 
analyzed the eluting peak by HRESIMS/MS using direct injection into the mass spectrometer 
device. Again, the target m/z value was observed and fragments corresponding to palmitic acid 
as well as its neutral loss were detected along with bartoloside A dialkylresorcinol fragments 
(annex figure 4).  
Figure 23. Extracted Ion Chromatograms (EICs) of putative esterified bartoloside A monopalmitate m/z 879.6486 [M-H]-. 
Depicted are fractions 14-20 derived from the flash chromatography performed with the crude extract obtained from 20 L of non-
supplemented S. salina LEGE 06099 containing the putative esterified bartoloside A monopalmitate m/z 879.6486 [M-H]-. 
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The obtained subfraction 15.7 (6.52 mg d.w.) was submitted to 1H NMR so that we could verify its 
purity and forward it to 2D NMR analyses for the structural elucidation. However, the data showed 
that a minor bartoloside co-eluted (likely the structural isomer of bartoloside A monopalmitate 5b) 
since the proton resonances were extremely close and overlapping (annex figure 3), thus further 
separation was necessary. 
Although methanol was efficient for a faster separation of fraction 15 we decided to test acetonitrile 
since it promoted a much slower peak elution. In fact, after some program adjustments we verified 
that 98% acetonitrile in water was the ideal to cause the proper separation of subfraction 15.7, 
even though the elution was occurring only after 120 minutes. Fraction 15.7.2 (3.1 mg, retention 
time ~122 minutes, figure 25) was then submitted to 1H NMR and since it was spectroscopically 
pure we proceeded with the 1D and 2D NMR analysis for the structural elucidation. 
Figure 24. Chromatograms obtained after RP-HPLC of fraction 15 using 99% acetonitrile in water (a) and 98% methanol in water (b). 
the collected subfractions (15.1-15.11) are evidenced by the numbers on top of the peaks or peak region in b).  
a) 
b) 
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 Structural elucidation of bartoloside A monopalmitate 5a 
The HRESIMS performed for compound 5a (isolated as a white glassy solid) presented a peak 
with m/z 879.6504 [M-H]- (calculated for C52H92O8Cl- m/z 879.6499), compatible with a molecular 
formula of C52H93O8Cl and 6 degrees of unsaturation. The 1H and 13CNMR data indicated the 
presence of the characteristic aromatic resorcinol ring and xylosyl group observed in bartolosides 
from S. salina LEGE 06099 (annex table 3). A carbonyl resonance was also present (δC 174.7) as 
observed for bartoloside esters 3 and 4. The additional C16H31O2 (compared to 1) was consistent 
with the esterification of one palmitic acid moiety with bartoloside A (1) and the concomitant loss 
of one chlorine atom (as seen for 3 and 4). Support to this hypothesis was gained from 
HRESIMS/MS analysis of the in-source-formed species with m/z 473.40032, which showed 
diagnostic fragments that are consistent with a backbone similar to that of 1 (figure 26), as well as 
from 2D NMR experiments: an HSQC correlation between δH 3.88 and δC 64.5, likely 
corresponding to a chlorinated methine, was part of a spin system that expanded, on both 
directions into degenerate CH2 resonances, indicated that this corresponded to a mid-chain 
chlorination, characteristic of the bartolosides (figure 27). HRESIMS/MS data was consistent with 
the presence of a palmitate-derived fragment (m/z 255.23 [M-H]-, figure 20). The 1D and 2D NMR 
data showed an additional methyl group (compared to 1) at the terminal position of an alkyl chain, 
as well as a bigger CH2 envelope, both in line with the presence of a palmitate moiety in compound 
5a. The oxymethine proton resonating at δH 4.88 presented HMBC correlations to C-1’ (δC 174.7) 
in the palmitate moiety and was itself part of another spin system that degenerated into CH2 
envelopes; hence it was likely positioned in the middle of the non-chlorinated alkyl chain. All these 
Figure 25. Chromatogram of purified subfraction 15.7.2 after a reverse phase semipreparative HPLC of fraction 15.7 using 
98% acetonitrile in water. 15.7 using 98% acetonitrile in water.  
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observations supported our proposal of 5a being a palmitate ester of 1. Because 1 has two 
halogenated methine moieties, to clarify which chain contained the esterification in 5a, we 
compared the 1H NMR spectra for 5a with the previously reported81-82 data for 1. Interestingly, we 
found that the multiplicity of H2-12 (δH 2.58) changed from a complex multiplet in bartoloside A to 
a triplet in 5a, while the multiplicity of H2-24 (δH 2.50) remained unaffected (figure 28). As such, 
we propose that position 17, in the same alkyl chain as the H2-12 benzylic protons, is esterified in 
bartoloside A-17-yl palmitate (5a). Further HRESIMS/MS analysis is consistent with this 
assignment (figure 26). 
Optical rotation, infrared (IR) and ultraviolet (UV) fingerprint: 
[α] 25D -9.2 (c 0.42, MeOH); IR (thin film) ʋmax 3417, 2923, 2854, 2360, 2340, 1730, 1704, 1592, 
1463, 1455, 1430, 1159, 1048, 1033 cm-1; UV (MeOH) λmax (log ε) 217 (3.3), 222 (3.3), 273 (2.9). 
Figure 26. HRESIMS/MS spectra for the in-source (collision energy of 90 eV) generated fragment of 5a
providing the required confirmation and validation of the chemical structure of compound 5a. 
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 Bioactivity of compounds 3, 4 and 5a 
Even though the alkyne moiety was not incorporated in the expected fashion we proceeded with 
some bioactivity assays using our new compounds 3 and 4, as well as the novel natural version 
of bartoloside A palmitate (5a). As previously reported, bartoloside A only had activity against the 
colorectal adenocarcinoma cell line HT-2982 which was our starting point for the assays using 
compounds 3, 4 and 5a (figure 29). Additionally, since we had isolated decent amounts of 
compounds 3 and 4 we decided to also screen their bioactivity against other cell lines available 
(hCMEC/D3 and HCT116, figures 30 and 31, respectively). However, none of the compounds had 
activity against these cell lines, with the exception of compounds 3 and 4 which presented low 
activity against hCMEC/D3, a blood-brain barrier cell line that has been immortalized, (but not a 
cancer-derived cell line). Regarding naturally occurring ester 5a, it seems that after the alkylation 
with palmitate bartoloside A loses the activity against HT-29. Furthermore, we exposed several 
Figure 28. 1H NMR-based assignment of which alkyl chain in 5a is esterified with palmitic acid. Shown are the structures and regions 
of the benzylic proton resonances for bartoloside A (1, top) and 5a (bottom). Resonance for protons of H2-24 (green) were not affected 
while protons H2-12 (pink) multiplicity was affected by the new palmitate moiety in 5a.  
Figure 27. Key HMBC and COSY correlations of bartoloside A-17-yl palmitate (5a). 
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bacteria along with the fungus Candida albicans to our isolated compounds but no antimicrobial 
activity was detected for any of the isolated natural products (figure 32). 
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Figure 30. Bioactivity assay results of exposed hCMEC/D3 cells to compounds 3 and 4 after 24h (a) and 48h (b). C+:1 µM 
staurosporine. 
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Figure 29. Bioactivity assay results of exposed HT-29 cells to compounds 3, 4 and 5a after 24h (a) and 48h (b). C+:1 µM staurosporine. 
FCUP 
A novel biocatalytic esterification involved in the biosynthesis of branched bartolosides 34 
 
0,0
0,1
0,2
0,3
0,4
0,5
0,6
C- C+ 100 
μM
50 
μM
25 
μM
10 
μM
1μM
O
D
5
5
0
n
m
48h exposure HCT116
0,0
0,1
0,2
0,3
0,4
0,5
C- C+ 100 
μM
50 
μM
25 
μM
10 
μM
1μM
O
D
5
5
0
n
m
24h exposure HCT116
a) b) 
Figure 31. Bioactivity assay results of exposed HTC116 cells to compounds 3 and 4 after 24h (a) and 48h (b). C+:1 µM staurosporine.
Figure 32. Tested bacterial and fungi strains. C: DMSO; 1- compound 3, 
2- compound 4; 3- compound 5a. 
FCUP 
A novel biocatalytic esterification involved in the biosynthesis of branched bartolosides 35 
Having established that bartoloside esters occur in Nature, we focused on the biochemical aspects 
of the observed esterification. In organic synthesis, several methods have been described for the 
formation of carboxyesters, usually exploiting the nucleophilic attack of an alcohol onto the 
carboxylic carbon, as described by the Fisher-Speier esterification.93 However, in the present 
reaction between bartolosides and fatty acids, the carboxylate seems to be acting as the 
nucleophile performing the attack onto the electrophilic alkyl halide chains of the bartolosides. 
Recent studies by Balskus and co-workers regarding CylK C-alkylation (see “Introduction” section) 
encouraged us to consider that BrtB, the only enzyme encoded in the brt cluster with no ascribed 
function, 81-82 could be responsible for the observed esterification. 
 Cloning of NStrep-BrtB 
To be able to understand if the ester formation in the bartolosides was promoted by BrtB we first 
needed to clone it into a suitable model for protein expression, such as Escherichia coli. We 
attempted at using the genomic DNA (gDNA) from S. salina LEGE 06099 (isolated using the 
PureLink™ Genomic DNA Mini Kit, Invitrogen), however, after running a 1% agarose gel 
electrophoresis we verified that the DNA was degraded. After additional attempts, we faced the 
same results and decided to perform the gDNA extraction using the cetyl trimethylammonium 
bromide (CTAB) procedure (figure 33a).  
Although the arguably most common procedure for recombinant protein expression and 
purification relies on the fusion of a polyhistidine tag (HisTag) into the gene sequence of the 
desired protein, we did not succeed in overexpressing the 6HisTag version of BrtB. After using 
both E. coli BL21 and E. coli BL21(DE3)pLysS competent cells we decided to analyze the protein 
sequence of the recombinant protein. The codon adaptation index (CAI)94 of the inserted gene 
was in fact relatively low (0.63) when crossed against the E. coli genome, indicating that we should 
try and use a different model for protein expression. Therefore, we tested the expression in E. coli 
Rosetta(DE3) since it contains a plasmid encoding for rare codons that could ameliorate 
transcription. The attempt failed again since we were not able to see any expression. At this point 
we started to consider protein solubility issues and a recently published study by the Balskus’ with 
a detailed purification of CylK, (BrtB homolog).90 In the new procedure, Balskus and co-authors 
described a protocol using a Strep-Tag©-recombinant version of CylK. This tag consists of an 
aminoacid sequence overhang (Trp-Ser-His-Pro-Gln-Phe-Glu-Lys) with binding affinity to a 
streptavidin analog, Strep-Tactin resin, working as an efficient affinity chromatography system.95 
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We decided to attempt the cloning and expression of Strep-Tag© fused BrtB. The primer design 
for the amplification of brtB was accomplished using both Geneious Prime 2019.0.4 and 
OligoCalc.96 This step consisted on the addition of two overhangs complementary to the restriction 
enzymes SalI (5’) and SacI(3’), which were the only enzymes in pET51b (+) (containing Strep-tag) 
that did not cut the internal sequence of brtB, originating a N-terminal Strep-Tag version of BrtB. 
Since the melting temperatures of the primers was considerably high and because we were using 
Phusion High-Fidelity DNA Polymerase (ThermoFisher), the PCR program consisted on a 2-step 
protocol at 72 C (see “Materials and Methods” section). After the purification and restriction 
digestion of both PCR product and vector pET51b (+) the ligation was promoted overnight at 16 
C. This ligation mixture was used to transform TOP10 E. coli competent cells as described in the 
“Materials and Methods” section. The extracted plasmid pET51b-NStrep-brtB was then used to 
transform chemically competent E. coli Rosetta(DE3) and E. coli BL21(DE3)pLysS. Obtained 
colonies were verified using PCR (figures 33c and d). 
 
Table 1. Primers used for the amplification of NStrep-brtB. Underlined are the complementary sequences of the restriction enzymes 
used. 
 
Primer name Primer sequence (5’ – 3’) Tm (C) % GC 
BrtB-NStrep-SalI-F AATGTCGACATGGCCAATCCCTTCG 59.3 52 
BrtB-NStrep-SacI-R ATATGAGCTCCTAGTAGCCGTACCCG 61.1 54 
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 Expression and purification of NStrep-BrtB 
Since we have followed the steps employed by Schultz et al. 90 regarding the use of Strep-Tag© 
technology we decided to replicate their procedures regarding protein expression. Both CylK and 
BrtB are predicted to be calcium dependent proteins81-82, 89-90 meaning that supplementing the 
growing E. coli Rosetta(DE3) with CaCl2 while adding isopropyl β-D-1-thiogalactopyranoside 
(IPTG) could promote the protein’s stability. However, after inducing both E. coli Rosetta(DE3) 
and BL21(DE3)pLysS, containing recombinant NStrep-brtB, and harvesting the cultures after 4 
and 16 hours, we did not obtain overexpression of our protein (91.4 kDa) verified in a SDS-PAGE 
gel (figure 34).  
Figure 33. Results from1% agarose gel electrophoresis of cloning procedures of NStrep-brtB. a) Genomic DNA of S. salina LEGE 
06099 was extracted using the Invitrogen Kit (Inv.) and with the cetyl trimethylammonium bromide (CTAB) method. b) PCR products 
(1-3) of brtB amplification after band excision and purification. c) Colony PCR results of TOP 10 E. coli colonies transformed with 1:3 
and 2:3 ligation mixture. d) Colony PCR results of E. coli BL21(DE3)pLysS and Rosetta(DE3) colonies transformed with purified pET51-
NStrep-brtB. M: GeneRuler 1 kb plus DNA ladder (Invitrogen); C-: PCR mixture without gDNA (only primers); C+: PCR mixture with 
gDNA from S. salina LEGE06099.  
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At this point, we considered that the target protein was insoluble inside the induced cells and 
prevented the efficient overexpression and detection. Indeed, Schultz et al. 90 faced the same 
issues and published two procedures for the expression and purification of CylK-Strep, one of 
them requiring protein refolding. However, such a protocol demanded high speed centrifugation 
technology and additional vectors which were not available in our facilities. Nevertheless, they 
were able to obtain 0.1 mg of CylK-Strep per liter of culture of a 2 L culture of an E. coli strain 
similar to Rosetta(DE3).90 For this reason we decided to test if we could obtain soluble NStrep-
BrtB from a 2 L culture of our E. coli Rosetta(DE3) harboring the pET51b-NStrep-brtB plasmid. 
After performing the affinity chromatography using a pre-packed StrepTactin Superflow column 
(Novagen) we were able to observe the desired recombinant protein NStrep-BrtB eluting mainly 
in fractions 3 to 7 (figure 35a). The purified protein was desalted and concentrated (see “Materials 
and Methods” section) and a yield of 0.3 mg of NStrep-brtB per liter of E. coli Rosetta(DE3) culture 
was obtained (figure 35b). 
Figure 34. SDS-PAGE results of NStrep-BrtB expression after 4h and 16h induction with IPTG and CaCl2 of both E. coli 
BL21(DE3)pLysS and Rosetta(DE3). Target protein has 91.4 kDa. M: Precision Plus Protein Standard (Biorad)); C1: empty pET51b 
(+) vector; C2: no induction control (no IPTG). 
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 Enzymatic assays using recombinant NStrep-BrtB 
To obtain biochemical evidence supporting that BrtB was responsible for the esterification of 
bartolosides we resorted to in vitro enzymatic assays of the protein’s activity. Since BrtB is 
predicted to be calcium dependent we performed the assays in a buffer containing Ca2+, as in the 
expression and purification. After incubating a mixture of bartoloside A (previously isolated by 
Leão and co-workers82) with both palmitic and 6-heptynoic acids, the reaction was quenched and 
the collected aliquots analyzed (0, 6 and 24h) by LC-HRESIMS/MS (figures 36 and 37, annex 
figure 5). The results (figures 36 and 37) showed that BrtB was able to catalyze the reaction 
between bartoloside A (1) and 6-heptynoic acid, generating both the bartoloside A mono- and 
diester of 6-heptynoate (8a/8b and 3, respectively). In line with the in vivo data, we were also able 
Figure 35. SDS-PAGE of the affinity chromatography performed (a) and the NStrep-BrtB after desalting and concentration (b). MW 
Marker: Precision Plus Protein Standard (Biorad)). Pooled fractions 3 to 7 are evidenced with a red rectangle.  
FCUP 
A novel biocatalytic esterification involved in the biosynthesis of branched bartolosides 40 
to verify the esterification of bartoloside A (1) with palmitic acid to generate bartoloside A palmitate 
(5a/5b) as well as bartoloside A dipalmitate (7), though in far less abundance and only after 24h 
(figure 37). Analysis of the controls without NStrep-BrtB (only 1 and fatty acids) showed the 
decrease in bartoloside A levels without the formation of any other peaks, which can potentially 
be explained by the degradation of compound 1 when in the presence of an acidic environment 
or by solubility issues caused by the presence of the fatty acids. 
Figure 36. BrtB converts bartoloside A (1) and 6-heptynoic acid into bartoloside esters 3 and 8a/8b in vitro. Depicted are the 
extracted ion chromatograms (EICs) obtained from LC-HRESIMS analysis of the assay containing NStrep-BrtB and control 
assays with either NStrep-BrtB or 6-heptynoic acid. 
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Together, our data show that BrtB catalyzes the C-O alkylation of the secondary alkyl halide 
moieties from bartolosides. As mentioned above, in organic synthesis, esterification processes 
usually rely on the nucleophilic attack of an alcohol onto a carboxylic carbon or carbonyl as typified 
in the Fisher-Speier esterification.93 Nevertheless, esterification reactions that are independent of 
alcohols and take advantage of the nucleophilicity of the carboxylate anion have also been 
described.97 Such reactivity can be found using primary alkyl halides as the electrophile but the 
Figure 37. BrtB converts bartoloside A (1) and palmitic acid into bartoloside esters 5a/5b and 7 in vitro. Depicted are the extracted 
ion chromatograms (EICs) obtained from LC-HRESIMS analysis of the assay containing NStrep-BrtB and control assays with either 
NStrep-BrtB or palmitic acid.  
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procedures usually rely on the application of expensive or even toxic intermediates, e.g. 
hexamethylphosphoramide (HMPA).98  
In biological chemistry, carboxylates acting as nucleophiles can also be found but require 
substrate activation by adenylation.99 Examples of such reactions can be found in the polyketide 
biosynthesis where alpha-keto acids and/or fatty acids are activated by adenosine triphosphate 
(ATP), through the formation of a bond between the carboxylate and phosphate of ATP, to 
generate an Acyl-AMP (adenosine monophosphate).99-100 Nevertheless, to undergo carboxyester 
formation these reactions rely on the nucleophilic attack onto an activated acyl carbon (through 
acylation of a suitable alcohol as in the lipase and esterase activities)101 or through direct oxidation 
by Bayer-Villiger monooxygenases34. To our knowledge, the single example in living organisms in 
which carboxyester formation is suggested to occur via a carboxylate nucleophile is in nosiheptide 
biosynthesis.102 NosN, encoded in the nos gene cluster, is reported as the responsible for the 
catalysis of an intramolecular reaction between a reactive exocyclic electrophilic intermediate and 
a glutamate residue (Glu6) of the structural peptide, generating an ester linkage and causing the 
macrolactonization in nosiheptide (figure 38).102 Furthermore, transient carboxyester formation 
has also been verified under the action of some haloalkane dehalogenases.103 For instance, the 
L-2-Haloacid dehalogenase from Pseudomonas sp. YL is proposed to catalyze the nucleophilic 
attack of carboxylate group from aspartate onto the α-carbon of the L-2-haloacid.104-105 Such ester 
intermediate will be later attacked by an water molecule activated by a basic amino acid from the 
enzyme, causing the hydrolysis of the ester intermediate and originating a hydroxylated version 
of the haloacid (figure 38).104-105 Even though these enzymes catalyze esterifications using a 
carboxylate nucleophile the reactivity and substrates behind their mechanisms are considerably 
different when compared to BrtB action (figure 38). With reference to nosiheptide biosynthesis, 
the initial substrate consists on a methylene moiety in the side-ring system of 3,4-dimethylindolic 
acid which has a clearly different reactivity when compared to a secondary alkyl halide as in the 
bartolosides. On the other hand, the L-2-haloacid dehalogenase also uses a secondary alkyl 
moiety, though there is carboxylic carbon withdrawing electron density from the halogenated α-
carbon, increasing its electrophilicity and causing this position to be more prone to the nucleophilic 
attack by the carboxylate than in the halogenated position of bartolosides. As such, BrtB is a novel 
enzyme responsible for an unprecedented O-alkylation of secondary alkyl halide moieties. 
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 Phylogenetic Analysis of BrtB homologs 
After establishing that BrtB is the enzyme responsible for the novel biocatalytic O-alkylation 
reaction behind the formation of bartoloside esters, we decided to look more closely to biosynthetic 
gene clusters containing BrtB homologs. To accomplish this, we performed a phylogenetic 
analysis and verified the presence of two major, well-supported clades of BrtB/CylK homologs 
within the dataset. One of the clades is composed by cyanobacterial homologs that are within 
biosynthetic gene clusters encoding for halogenases, while the other clade was formed by 
essentially non-cyanobacterial sequences. Interestingly, within this larger clade, BrtB homologs 
diverge into an independent sub-clade from CylK homologs, involved in the biosynthesis of 
Figure 38. Selected O-alkylating enzymes. A exomethylene intermediate is generated by NosN, a SAM depedent enzyme, which will 
then drive an intramolecular ester bond formation. Dehalogenation of alkyl halides catalyzed by L-2-haloacid dehalogenase involves 
the formation of an ester species, which results from the nucleophilic attack of a side chain carboxylate onto the chlorinated position 
of the haloacid. BrtB catalyzes a C-O alkylation between non-activated fatty acids and bartolosides. 
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different cyclophanes. Annotation of the putative BGC within both these BrtB/CylK clades 
indicated that these gene clusters conspicuously encode for type I polyketide synthases, fatty acid 
activating enzymes, non-ribosomal peptide synthetases and varied tailoring functionalities. For 
instance, Anabaena cylindrical PCC 7122 contains a putative BGC interestingly similar to brt, with 
the presence of a BrtJ (halogenase) homolog, possibly encoding for bartoloside-like secondary 
Figure 39. Phylogenetic analysis of BrtB homologs (left) and exemples of putative biosynthetic gene cluster
containing BrtB/CylK homologs. 
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metabolites. Knowing this, our phylogenetic analysis along with previous reported data89 strongly 
suggest that BGCs encoding CylK/BrtB-like enzymes from cyanobacteria represent prospects for 
the discovery of novel enzymatic reactivity and natural product chemistry. 
III. Final Remarks 
Taking into consideration that the biosynthesis of bartolosides require the recruitment of fatty acid 
derivatives from primary metabolism, we anticipated that by supplying terminal alkyne fatty acids 
to S. salina LEGE 06099 (a major bartoloside producer) cultures, we would obtain click chemistry-
accessible versions of the bartolosides. However, the attempt to incorporate terminal alkyne 
moieties into previously known bartolosides failed and instead led to the discovery and later 
isolation of two compounds (3 and 4), formed upon supplementation, that were elucidated and 
confirmed to be bartoloside esters of the supplemented fatty acid 6-heptynoate. We eventually 
detected putative natural occurring bartoloside A palmitate, suggesting that the esterification in 
bartolosides could happen without supplementation of exogenous fatty acids. After successfully 
isolating and structurally elucidating bartoloside A palmitate (5a) we concluded that the previously 
reported bartolosides were not, in all likelihood, the end-product of the brt gene cluster. These 
findings drove us to perform in vitro experiments to determine the function of the only enzyme in 
the bartolosides gene cluster without ascribed function. Overall, we show that BrtB is a novel 
enzyme responsible for the catalysis of free (non-activated) fatty acids with the chlorinated 
positions found in the bartolosides, generating a significant diversity of branched bartolosides. 
Such reactivity has only been transiently observed in intermediaries formed by haloalkane 
dehalogenases action. BrtB is the second enzyme of its family to be characterized, along with the 
Friedel-Crafts alkylating enzyme CylK.89 Phylogenetic analysis of CylK/BrtB-like enzymes 
revealed a series of putative cyanobacterial biosynthetic gene clusters that paved the way to the 
discovery of novel biocatalytic reactivity and natural product architecture. Furthermore, the 
relatively high abundance of these bartolosides indicates that there must exist an important 
biological role for such secondary metabolites. Bearing in mind the conspicuous depletion of 
bartolosides in the presence of exogenously supplied free fatty acids, we speculate that the 
formation of bartoloside esters, by BrtB, might represent a fatty acid storage or scavenging 
mechanism. 
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IV. Materials and Methods 
 Cyanobacterial culture conditions 
The cyanobacterium Synechocystis salina LEGE 06099 was obtained from the LEGEcc.106 
Cultures were grown in Z8 medium supplemented with 25 g L-1 sea salts (Tropic Marin), at 25 °C, 
under a 14:10 h light/dark cycle and constant aeration. For the feeding studies with 5-hexynoic 
and 6-heptynoic acids, small-scale cultures were inoculated to a final OD750nm of 0.04~0.1 while 
large scale cultures (20 L) were inoculated using 1.5 L of stationary phase cultures. Feeding 
experiments with other substrates used a 3:50 inoculum of stationary phase cultures. 
 Feeding experiments 
Supplementation with 5-hexynoic and 6-heptynoic acids: 
Feeding experiments of S. salina LEGE 06099 cultures (in Z8 medium, see above) were 
performed through the supplementation of 5-hexynoic acid or 6-heptynoic acid to a final 
concentration of 50 mg L-1 from a 1000 concentrated solution of each acid in DMSO. The 
experiments were carried out in 100 mL cultures in Erlenmeyer flasks and cells were harvested 
after 30 days by centrifugation at 4500 g for 10 min at 4 °C, rinsed with deionized H2O and 
centrifuged again. The resulting biomass pellets were lyophilized prior organic extraction (see 
section “Organic extraction”). Crude extracts were analyzed by LC-HRESIMS and LC-
HRESIMS/MS. 
Supplementation with other substrates: 
A similar procedure was used for supplementation with 7-bromoheptanoic, trans-3-hexenedioic, 
hexylphosphoric, caprylic, butyric, lauric and palmitic acids as well as hexanamide and 
hexylalcohol but a final concentration of each substrate of 0.4 mM was used. Cells were harvested 
after three days of exposure and organic extraction (see section “Organic extraction”) was 
performed without prior lyophilization. The resulting crude extracts were analyzed by LC- 
HRESIMS. 
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 Large-scale S. salina LEGE 06099 cultivation 
In order to obtain sufficient biomass to isolate sufficient amounts of bartoloside esters formed upon 
supplementation for structure elucidation, a 20 L culture of S. salina LEGE 06099 was prepared 
in Z8 medium supplemented with 6-heptynoic acid (50 mg L-1), as described above. After a 45-
day growth period, the biomass was harvested by centrifugation (4500 g, 10 min, 4 °C), washed 
with deionized water and centrifuged again. The corresponding pellet was freeze-dried and stored 
at -20 °C until further use. 
For the isolation of bartoloside esters formed without any supplementation (instead, 0.5% DMSO 
was added to the culture), a 20 L culture of S. salina LEGE 06099 was grown in Z8 medium during 
30 days and the biomass was collected as previously described. 
 Organic extraction 
For the small scale cultures (100 mL) the organic extraction was carried through repeated 
percolation using a mixture of CH2Cl2/MeOH (2:1, v/v) at room temperature while for the large 
scale cultures (20 L) the extraction was carried both at room temperature and at 40 °C. Solvent 
volume depended on the sample size. The solvent was removed in vacuo and the extract stored 
at – 20 ºC until further use. 
 LC-HRESIMS analysis 
For LC-HRESIMS analyses, separation was performed in a Luna C18 column (100  3 mm, 3 µm, 
100 Å, Phenomenex). Mixtures of MeOH/H2O 1:1 (v/v) with 0.1% formic acid (eluent A) and 
isopropanol (IPA) with 0.1% formic acid (eluent B) were used as mobile phase, with a flow rate of 
0.4 mL min-1. Depending on the sample to be analyzed, different elution programs and injection 
volumes/concentrations were used, as detailed below.  
LC-HRESIMS of samples derived from feeding with 5-hexynoic and 6-heptynoic acids: 
Crude extracts and flash chromatography fractions obtained from the initial feeding experiments 
were separated (10 µL of a 1 mg mL-1 solution were injected) using a gradient from 9:1 to 3:7 
eluent A/eluent B in 10 min and held for 7 min before returning to the initial conditions. 
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LC-HRESIMS of samples derived from feeding with other substrates: 
Crude extracts obtained from feeding experiments with 7-bromoheptanoic, trans-3-hexenedioic, 
hexylphosphoric, caprylic, butyric, lauric and palmitic acids, hexanamide and hexylalcohol were 
separated (10 µL of a 1 mg mL-1 solution were injected) using a gradient from 9:1 to 3:7 eluent 
A/eluent B in 10 min and held for 12 min before returning to the initial conditions. 
LC-HRESIMS of samples derived from 20 L culture of S. salina LEGE 06099 without feeding: 
Crude extracts of biomass from cultures that were not supplemented with fatty acids were 
analyzed by LC-HRESIMS using a gradient from at 9:1 to 1:4 eluent A/eluent B in 3 min and held 
for 28 min before returning to initial conditions. Fractions obtained from semipreparative HPLC 
during purification of natural bartoloside esters were analyzed (10 µL at 1 mg mL-1 per injection) 
using a similar program, but with an isocratic step of only 24 min. Semipreparative HPLC 
subfractions that were analyzed by LC- HRESIMS/MS were separated (10 µL at 0.5 mg mL-1 
injected) using a gradient from 9:1 to 7:13 eluent A/eluent B in 5 min, increasing to 3:7 eluent 
A/eluent B over 15 min and holding the isocratic for additional 5 min before returning to initial 
conditions. 
LC-HRESIMS of enzymatic reaction samples: 
Analysis of enzymatic reaction samples was carried out by injecting 10 µL of supernatant from the 
methanol/acetonitrile-quenched reaction mixture (see Enzymatic assays). Separation involved an 
isocratic step of 9:1 eluent A/eluent B over 2 min, followed by a linear gradient to 7:13 eluent 
A/eluent B over 3 min and held for 10 min before returning to the initial conditions. 
 HRESIMS/MS analysis 
MS/MS parameters for the LC-HRESIMS/MS analysis of crude extracts, HPLC fractions and 
enzymatic assays were: resolution of 35000, with a 1 m/z isolation window, a loop count of 3, AGC 
target of 5104 and collision energy of 35 eV. 
HRESIMS/MS analysis of purified compounds 3 and 4 was performed by direct injection (0.1 mg 
mL-1 solutions) into the spectrometer, using a resolution of 35000, a 1 m/z isolation window, a loop 
count of 3 and an AGC target of 5  104. Stepped collision energies of 35, 40 and 45 eV were 
applied. To obtain structural information regarding the dialkylresorcinol moiety, isolation of 
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insource-formed species were selected for ddMS2 events. For purified compounds 3 and 4, the 
in-source collision induced dissociation (CID) energy was set to 90 and 65 eV, respectively (to 
isolate species corresponding to loss of xylosyl, one C7H9O and C7H9O2 for 3 as well as loss of 
xylosyl and C7H9O for 4), resolution of 35000, with 1 m/z isolation window, loop count of 1 and 
AGC target of 5  104. CID energy was set to 55 eV. For purified compound 5a the in-source 
collision energy was set to 90 eV (to isolate a species corresponding to the loss of xylosyl and 
HCl). 
 NMR, spectrometry and spectroscopy analysis 
One- and two-dimensional NMR spectra were obtained on a Bruker Avance III, 400 MHz, in the 
Materials Center of the University of Porto (CEMUP). Chemical shifts are reported in parts per 
million (ppm) and using the residual solvent resonances as reference for 1H (CDCl3, H= 7.26 ppm) 
and 13C (CDCl3, C= 77.16 ppm). Optical rotation was measured in a P-2000 polarimeter (JAS.CO). 
Infrared spectra were acquired in a Nicolet iS5 FTIR spectrometer (ThermoScientific). UV spectra 
were obtained from a UV-1600PC spectrometer (VWR). 
 Fractionation and isolation of branched bartolosides 
Isolation of bartoloside esters 3 and 4: 
The crude extract (754.6 mg) obtained from a 20 L culture of S. salina LEGE 06099 in Z8 medium 
supplemented with 6-heptynoic acid (details in “Feeding Experiments” section) was fractionated 
by normal phase flash chromatography (Si gel 60, 0.040-0.063 mm, Macherey Nagel) using a 
gradient of increasing polarity gradient from hexane to EtOAc to MeOH, yielding eight fractions 
(1-8). Fraction 5 (102.2 mg), eluting with a 2:3 mixture of EtOAc/hexane was further separated by 
RP-semipreparative HPLC with a ACE C18 column (100 Å pore size, 250  10 mm, 5 μm) (ACE). 
Mobile phase A was ddH2O and mobile phase B was MeCN (aq). The LC method used a constant 
flow rate of 3 mL min-1 with an isocratic step 8% A, 92% B over 25 min followed by a gradient to 
100% B over 2 min and held for 15 minutes before returning to the initial conditions. This procedure 
afforded 10 subfractions. Fractions 5.6 (compound 3, 48.0 mg, tR = 13.5 -15.0 min) and 5.10 
(compound 4, 4.3 mg, tR = 24.0 – 25.0 min) were spectroscopically pure (>95%, 1H NMR), showing 
signals characteristic of bartolosides.81-82 
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Isolation of bartoloside ester 5a: 
The resulting organic extract (574.3 mg) from 20 L culture of S. salina LEGE 06099 was 
fractionated by normal phase flash chromatography (Si gel 60, 0.040-0.063 mm, Macherey-
Nagel). An increasing polarity gradient from hexane to EtOAc to MeOH was used for elution. The 
collected fractions were pooled according to their TLC profiles, affording 23 sub-fractions (1-23). 
Sub-fraction 15, eluting with 2:3 and 1:1 EtOAc/hexane, contained m/z 879.648 (5a/5b, [M-H]-), 
as verified by LCHRESIMS analysis, and was further fractionated by RP-semipreparative HPLC 
(ACE C18, 250  10 mm, 5 μm, 100 Å, ACE), using 98% MeOH (aq) isocratically over 65 minutes 
and with a flow rate of 3 mL min-1. 1H NMR analysis showed that a minor bartoloside co-eluted 
(likely compound 5b), and thus further separation was necessary. Fraction 15.7 (tR= 32.1 – 34.5 
min) was reinjected into the RP-semipreparative system using the above-mentioned column and 
further separated with 98% MeCN (aq) to yield metabolite 5a (3.1 mg, tR ~122 min). 1H NMR 
analysis indicated that the compound was pure (>95%) and showed characteristic resonances for 
bartolosides.81-82 
 Cloning of brtB 
Genomic DNA from S. salina LEGE 06099 was extracted using the PureLink™ Genomic DNA 
MiniKit (Invitrogen) and CTAB method but only the second was used for the PCR amplification of 
brtB using primers BrtB-NStrep-SalI-F and BrtB-NStrep-SacI-R, which contained restriction sites 
for SalI and SacI, respectively. The reaction was prepared in a volume of 20 μL, containing 
1Phusion HF Buffer, 400 μM dNTPs, 0.5 μM of each primer, 0.4U Phusion polymerase 
(ThermoScientific) and 2 μL of template gDNA. The PCR cycling program consisted in a two-step 
protocol with extension at 72 C for 1.5 min. PCR products were gel purified (Illustra GFX PCR 
DNA and Gel Band Purification kit, GE Healthcare), restriction digested using SalI and SacI 
(Thermo Scientific) for 1.5 h at 37 C and gel purified again. Plasmid purifications were performed 
using NZYMiniprep (NZYTech). Digests were ligated into linearized StrepTag-containing pET-51b 
(+), using T4 DNA Ligase at 16 C overnight. 
Competent E. coli TOP10 cells were transformed with a 5 μL ligation sample by incubating the 
mixture on ice for 30 min, heat shocking at 42 C for 45 s and recovering on ice for 2 min. Then, 
250 μL of warm S.O.C. medium was added, the mixture was incubated at 37 C for 1 h and 100 
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μL of cells was plated on LB agar supplemented with 100 μg mL-1 ampicillin. The plate was 
incubated overnight at 37 C. Individual colonies were inoculated into 5 mL of LB supplemented 
with 100 μg mL-1 ampicillin and grown overnight at 37 C with 175 rpm shaking. The purified 
plasmids were sequenced to verify construct identity and amplification fidelity. pET-51b-NStrep-
brtB was transformed into chemically competent E. coli BL21(DE3)pLysS and Rosetta (DE3) by 
incubating the plasmid and cells on ice for 30 min and 5 min, respectively, applying a heat-shock 
at 42 C for 45 s and recovering for 2 min on ice. Then, 80 μL of warm S.O.C. medium was added, 
the mixture was incubated at 37 C for 1 h and 70 μL of cells was plated on LB agar supplemented 
with 100 μg mL-1 ampicillin and 34 μg mL-1 chloramphenicol. Individual colonies were inoculated 
into 5 mL of LB supplemented with 100 μg mL-1 ampicillin and 34 μg mL-1 chloramphenicol and 
grown overnight at 37 C with 175 rpm shaking. The resulting transformants were frozen in 
LB/glycerol 1:1 (v/v) stocks and stored at -80 C. 
 Small-scale NStrep-BrtB expression tests 
Glycerol stocks of E. coli BL21(DE3)pLysS and Rosetta (DE3) harboring the pET-51b-NStrep-brtB 
plasmid were used to prepare 50 mL cultures in LB medium supplemented with 100 μg mL-1 
ampicillin and 34 μg mL-1 chloramphenicol. Cultures were incubated at 37 C with 190 rpm and 
transferred to 15 C after reaching OD600nm=0.4. Induction was carried at OD600nm=0.6-0.7 with 0.5 
mM IPTG and supplemented with 5 mM CaCl2. 
After 4h and 16h of induction 20 mL of each culture were centrifuged (3000 g, 10 min, 4 C 
(Gyrozen 2236R, Rotor GRF-L-85-6), the pellets washed with Phosphate-buffered saline (PBS), 
centrifuged again and stored at -20 ºC. Pellets were resuspended in 500 µL of lysis buffer (50 mM 
Tris-HCl, 200 mM NaCl, 5% glycerol, 1 mM DTT and 20 mM CaCl2, pH 8.0) supplemented with 
1 Halt Protease Inhibitor Cocktail, lysozyme was added to a final concentration of 300 µg/mL The 
mixtures were incubated at 4 C for 4h and 10 mM MgCl2 was added to each tube and incubated 
again for additional 30 min. the samples were centrifuged (17000 g, 30 minutes, 4 C). Collected 
samples analyzed by SDS-PAGE (4-20% Mini-PROTEAN TGX precast gel, BIO-RAD). The gels 
were washed with ddH2O for 15 min, stained with Coomassie Blue G250 BioSafe (BioRad) for 1h 
and washed again. 
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 Expression and purification of NStrep-BrtB in E. coli Rosetta(DE3) 
A glycerol stock of E. coli Rosetta (DE3) harboring the pET-51b-NStrep-brtB plasmid was used to 
prepare a 50 mL starter culture in LB medium supplemented with 100 μg mL-1 ampicillin and 34 
μg mL-1 chloramphenicol. The starter culture was incubated overnight at 37 C with 175 rpm 
shaking. The overnight culture was used to inoculate (1:100 dilution) 2 L of LB medium 
supplemented with 100 μg mL-1 ampicillin and 34 μg mL-1 chloramphenicol. The culture was 
incubated at 37 C with 190 rpm shaking. At OD600nm=0.4-0.5 the culture was transferred to 15 C 
and orbital shaking decreased to 175 rpm. Once the culture reached OD600nm=0.8-0.9, protein 
expression was induced with 500 μM IPTG and the culture supplemented with 5 mM CaCl2. After 
four additional hours of incubation at 15 C with 175 rpm shaking, the cells were harvested by 
centrifugation (3000 g, 10 min, 4 C), washed with PBS and re-centrifuged. The pellet was flash 
frozen in liquid nitrogen and stored at -80 C until it was resuspended in lysis buffer (50 mM Tris-
HCl, 500 mM NaCl, 20 mM CaCl2, 10 mM MgCl2, 1 mM EDTA, pH 8.0) to which Pierce Protease 
Inhibitor Mini Tablets EDTA-free were added according to the manufacturer’s instructions (Thermo 
Scientific). The cells were lysed in a cell disruptor (CF Range, Constant Sytems Ltd) by a single 
cycle at 20000 psi and the lysate was clarified by centrifugation (19500 g, 30 min, 4 C). A pre-
packed 1 mL StrepTactin Superflow column (Novagen) was equilibrated with 2 mL of lysis buffer 
at 4 C for 45 min and the clarified lysate was transferred to the column, discarding the flow-
through. The column was washed with 5 mL lysis buffer and the protein was eluted in multiple 500 
μL fractions using elution buffer (100 mM Tris-HCl, 500 mM NaCl, 20 mM CaCl2, 10 mM MgCl2, 1 
mM EDTA, 2.5 mM desthiobiotin, pH 8.0). The collected fractions were analyzed by SDS-PAGE 
(4-20% Mini-PROTEAN TGX precast gel, BIO-RAD). Fractions containing the desired protein 
(~91.4 kDa) were pooled and desalted using PD-10 desalting columns (GE Healthcare). The 
columns were equilibrated with storage buffer (50 mM Tris-HCl, 50 mM NaCl, 10 mM MgCl2, 10 
mM CaCl2 and 10% glycerol, pH 8.0) and the protein sample was loaded into the columns (up to 
2.5 mL per column) and eluted with 3.5 mL storage buffer. The sample was concentrated to 34.6 
μM using Pierce™ Protein Concentrator tubes, 10K MWCO (Thermo Scientific) through two 
consecutive 15 min centrifugations (8000 g, 4 C). The concentrated protein was frozen in liquid 
nitrogen as pellets and stored at –80 C. This procedure yielded 0.3 mg of NStrep-BrtB per L of 
E. coli culture. 
FCUP 
A novel biocatalytic esterification involved in the biosynthesis of branched bartolosides 53 
 Enzymatic assays 
In vitro enzymatic assays were carried out in Eppendorf tubes to a final volume of 100 μL in 
reaction buffer (50 mM Tris-HCl, 50 mM NaCl, 10 mM MgCl2, 5 mM CaCl2, pH = 8.0). Final 
concentrations of each substrate were 1 μM for NStrep-BrtB, 100 μM for bartoloside A (1) and 200 
μM for both 6-heptynoic and palmitic acids and the reactions were incubated at 37 °C with 180 
rpm shaking. Aliquots (30 μL) were collected at 0, 6 and 24h and quenched with 60 μL of a cold 
mixture of MeOH/MeCN (1:1, v/v), vortexed immediately and incubated in ice for 10 min. 
Quenched reactions were then centrifuged at 17 000 g, 4 °C) and analyzed by LC-HRESIMS/MS. 
 Phylogenetic analysis 
Amino acid sequences of the BrtB homologs with lowest e-value (BlastP) were retrieved from the 
NCBI database (232 homologs retrieved). Their amino acidic sequences were aligned, together 
with those of a set of the distantly related virginiamycin lyases and alginate C5-epimerases and 
with the sequence of BrtB, using MUSCLE, from within Geneious R11 (Biomatters). The resulting 
alignment (with a total of 239 sequences) was trimmed to its core region and contained 1558 
positions. FastTree 2.1.528 (from within Geneious R11) was used to compute an approximately-
maximum-likelihood phylogenetic tree, using pseudocounts and 1000 rate categories of sites. 
 Bioactivity assays 
Animal cell line assays: 
All cell lines were sub-cultivated and grown in supplemented medium as recommended by the 
providers. All HCT116 colon carcinoma cell lines were maintained in McCoy’s 5A modified medium 
while HT-29 and hCMEC/D3 cell lines were maintained in Dulbecco’s Modified Eagle Medium 
(DMEM). All media were also supplemented with 10% fetal bovine serum (Biochrom), 1% of 
penicillin/streptomycin (Biochrom), and 0.1% of Amphotericin B (GE Healthcare), and all cells lines 
incubated at 37 °C in 5% CO2. 
For the bioactivity assays cells were seeded at 3.3 × 104 cells mL−1 in 96 well-plates, exposed to 
compounds 3, 4 and 5a after 24h and kept in the incubator for 24 and 48 h. All compounds were 
prepared in 100 concentrated stock solutions dissolved in dimethylsulphoxide (DMSO). A volume 
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of 1 µL of each stock solution was added to each well to a final concentration of 0.1% DMSO; 
negative control wells received solvent only; positive control used a solution of staurosporine 
dissolved in DMSO and was added to a final concentration of 1 µM. After the exposure, 3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT) was added at a final concentration 
of 0.05 mg ml−1 per well for 3 h. The formation of formazan crystals was visually evaluated by 
microscopy, dissolved in DMSO and absorbance measured at 550 nm on a Synergy HT Microplate 
Reader (Biotek). 
Antimicrobial susceptibility assay: 
Solutions of 0.5 mg mL-1 of compounds 3, 4 and 5a prepared in DMSO were tested against Gram-
positive bacterial strains (Staphylococcus aureus ATCC 29213), Gram-negative bacterial strains 
(Escherichia coli ATCC 25922 and Salmonella typhimurium ATCC 25241) and against a yeast 
strain (Candida albicans ATCC 10231). The bacteria were grown in Mueller-Hinton agar (MH – 
BioKar diagnostics) from stock cultures and incubated at 37 C. The yeast was grown in 
Sabouraud Dextrose Agar (BioKar diagnostics). For the antibacterial screening, a method of disc 
diffusion was carried out. Bacterial pure colonies were picked from overnight cultures in MH and 
suspended in LB liquid medium, the turbidity adjusted to OD600nm= 0.090-0.110 (0.5 McFarland 
standard) and the MH plates seeded with the resulting inoculum. Blank discs (6 mm in diameter, 
Oxoid) were placed in the inoculated plates and impregnated with 15 μL of a 0.5 mg mL-1 solution 
of each compound. The plates were left for 30 min at room temperature and then incubated 
overnight at 37 C. After 24h, the plates were checked for inhibition halos, indicative of 
antimicrobial activity. The diameter of inhibition halos was recorded. A disc with 15 μL DMSO was 
used as negative control. 
FCUP 
A novel biocatalytic esterification involved in the biosynthesis of branched bartolosides 
55 
V. References 
1. Fleming, A., On the antibacterial action of cultures of a penicillium, with special reference 
to their use in the isolation of B. influenzae. 1929. B World Health Organ 2001, 79 (8), 780-90. 
2. Pye, C. R.; Bertin, M. J.; Lokey, R. S.; Gerwick, W. H.; Linington, R. G., Retrospective 
analysis of natural products provides insights for future discovery trends. Proc Natl Acad Sci U S 
A 2017, 114 (22), 5601-5606. 
3. Vaishnav, P.; Demain, A. L., Unexpected applications of secondary metabolites. 
Biotechnol Adv 2011, 29 (2), 223-9. 
4. Craney, A.; Ahmed, S.; Nodwell, J., Towards a new science of secondary metabolism. J 
Antibiot (Tokyo) 2013, 66 (7), 387-400. 
5. Cragg, G. M.; Newman, D. J., Natural products: a continuing source of novel drug leads. 
Biochim Biophys Acta 2013, 1830 (6), 3670-3695. 
6. Sertuerner, Ueber das Morphium, eine neue salzfähige Grundlage, und die Mekonsäure, 
als Hauptbestandtheile des Opiums. Annalen der Physik 1817, 55 (1), 56-89. 
7. Buss, A. D.; Cox, B.; Waigh, R. D., Natural Products as Leads for New Pharmaceuticals. 
Burger's Medicinal Chemistry and Drug Discovery 2003, 847-900. 
8. Dias, D. A.; Urban, S.; Roessner, U., A historical overview of natural products in drug 
discovery. Metabolites 2012, 2 (2), 303-36. 
9. Chassagne, F.; Cabanac, G.; Hubert, G.; David, B.; Marti, G., The landscape of natural 
product diversity and their pharmacological relevance from a focus on the Dictionary of Natural 
Products®. Phytochem Rev 2019. 
10. Bérdy, J., Bioactive Microbial Metabolites. J Antibiot (Tokyo) 2005, 58, 1. 
11. Patridge, E.; Gareiss, P.; Kinch, M. S.; Hoyer, D., An analysis of FDA-approved drugs: 
natural products and their derivatives. Drug Discov Today 2016, 21 (2), 204-7. 
12. Baltz, R., Antimicrobials from actinomycetes: Back to the future. Microbe 2007, 2, 125-
131. 
13. Demain, A. L., Importance of microbial natural products and the need to revitalize their 
discovery. J Ind Microbiol Biot 2014, 41 (2), 185-201. 
14. Hinshaw, H. C.; Pyle, M. M.; Feldman, W. H., Streptomycin in tuberculosis. Am J Med 
1947, 2 (5), 429-435. 
15. Schatz, A.; Bugle, E.; Waksman, S. A., Streptomycin, a Substance Exhibiting Antibiotic 
Activity Against Gram-Positive and Gram-Negative Bacteria.∗†. P Soc Exp Biol Med 1944, 55 (1), 
66-69. 
16. Yan, Y.; Liu, Q.; Jacobsen, S. E.; Tang, Y., The impact and prospect of natural product 
discovery in agriculture: New technologies to explore the diversity of secondary metabolites in 
plants and microorganisms for applications in agriculture. EMBO Rep 2018, 19 (11). 
17. Demain, A. L.; Sanchez, S., Microbial drug discovery: 80 years of progress. J Antibiot 
(Tokyo) 2009, 62 (1), 5-16. 
18. Cantrell, C. L.; Dayan, F. E.; Duke, S. O., Natural Products As Sources for New Pesticides. 
J Nat Prod 2012, 75 (6), 1231-1242. 
19. Singh, R.; Kumar, M.; Mittal, A.; Mehta, P. K., Microbial metabolites in nutrition, healthcare 
and agriculture. 3 Biotech 2017, 7 (1), 15. 
20. Burg, R. W.; Miller, B. M.; Baker, E. E.; Birnbaum, J.; Currie, S. A.; Hartman, R.; Kong, Y. 
L.; Monaghan, R. L.; Olson, G.; Putter, I.; Tunac, J. B.; Wallick, H.; Stapley, E. O.; Oiwa, R.; 
Omura, S., Avermectins, new family of potent anthelmintic agents: producing organism and 
fermentation. Antimicrob Agents Chemother 1979, 15 (3), 361-367. 
FCUP 
A novel biocatalytic esterification involved in the biosynthesis of branched bartolosides 
56 
21. Wolstenholme, A. J.; Rogers, A. T., Glutamate-gated chloride channels and the mode of 
action of the avermectin/milbemycin anthelmintics. Parasitology 2005, 131 (S1), S85-S95. 
22. Sen, T.; Barrow, C. J.; Deshmukh, S. K., Microbial Pigments in the Food Industry-
Challenges and the Way Forward. Front Nutr 2019, 6, 7-7. 
23. Stevenson, C. S.; Capper, E. A.; Roshak, A. K.; Marquez, B.; Grace, K.; Gerwick, W. H.; 
Jacobs, R. S.; Marshall, L. A., Scytonemin--a marine natural product inhibitor of kinases key in 
hyperproliferative inflammatory diseases. Inflamm Res 2002, 51 (2), 112-4. 
24. Guerin, M.; Huntley, M. E.; Olaizola, M., Haematococcus astaxanthin: applications for 
human health and nutrition. Trends Biotechnol 2003, 21 (5), 210-6. 
25. Khan, R. A., Natural products chemistry: The emerging trends and prospective goals. 
Saudi Pharm J 2018, 26 (5), 739-753. 
26. Truppo, M. D., Biocatalysis in the Pharmaceutical Industry: The Need for Speed. ACS Medl 
Chem Lett 2017, 8 (5), 476-480. 
27. Turner, N. J.; Truppo, M. D., Biocatalysis enters a new era. Curr Opin Chem Biol 2013, 17 
(2), 212-4. 
28. Dalhoff, C.; Hüben, M.; Lenz, T.; Poot, P.; Nordhoff, E.; Köster, H.; Weinhold, E., Synthesis 
of S-Adenosyl-L-homocysteine Capture Compounds for Selective Photoinduced Isolation of 
Methyltransferases. ChemBioChem 2010, 11 (2), 256-265. 
29. Tengg, M.; Stecher, H.; Offner, L.; Plasch, K.; Anderl, F.; Weber, H.; Schwab, H.; Gruber-
Khadjawi, M., Methyltransferases: Green Catalysts for Friedel–Crafts Alkylations. ChemCatChem 
2016, 8 (7), 1354-1360. 
30. Holtmann, D.; Fraaije, M. W.; Arends, I. W.; Opperman, D. J.; Hollmann, F., The taming of 
oxygen: biocatalytic oxyfunctionalisations. Chem Commun (Camb) 2014, 50 (87), 13180-200. 
31. Woodley, J. M., Protein engineering of enzymes for process applications. Curr Opin Chem 
Biol 2013, 17 (2), 310-316. 
32. Hilker, I.; Wohlgemuth, R.; Alphand, V.; Furstoss, R., Microbial transformations 59: first 
kilogram scale asymmetric microbial Baeyer-Villiger oxidation with optimized productivity using a 
resin-based in situ SFPR strategy. Biotechnol Bioeng 2005, 92 (6), 702-710. 
33. Mihovilovic, Marko D.; Müller, B.; Stanetty, P., Monooxygenase-Mediated Baeyer−Villiger 
Oxidations. Eur J Org Chem 2002, 2002 (22), 3711-3730. 
34. Leisch, H.; Morley, K.; Lau, P. C., Baeyer-Villiger monooxygenases: more than just green 
chemistry. Chem Rev 2011, 111 (7), 4165-222. 
35. Bernan, V. S.; Greenstein, M.; Maiese, W. M., Marine Microorganisms as a Source of New 
Natural Products. Adv Appl Microbiol 1997 (43), 57-90. 
36. Fenical, W.; Jensen, P. R., Developing a new resource for drug discovery: marine 
actinomycete bacteria. Nat Chem Biol 2006, 2 (12), 666-73. 
37. Montaser, R.; Luesch, H., Marine natural products: a new wave of drugs? Future Med 
Chem 2011, 3 (12), 1475-89. 
38. Demay, J.; Bernard, C.; Reinhardt, A.; Marie, B., Natural Products from Cyanobacteria: 
Focus on Beneficial Activities. Mar Drugs 2019, 17 (6). 
39. Leao, P. N.; Engene, N.; Antunes, A.; Gerwick, W. H.; Vasconcelos, V., The chemical 
ecology of cyanobacteria. Nat Prod Rep 2012, 29 (3), 372-91. 
40. Kasting, J. F.; Siefert, J. L., Life and the Evolution of Earth's Atmosphere. Science (New 
York) 2002, 296 (5570), 1066. 
41. Flores, E.; Herrero, A., Compartmentalized function through cell differentiation in 
filamentous cyanobacteria. Nat Rev Microbiol 2009, 8, 39. 
42. Wase, N. V.; Wright, P. C., Systems biology of cyanobacterial secondary metabolite 
production and its role in drug discovery. Expert Opin Drug Dis 2008, 3 (8), 903-29. 
43. Marner, F.-J.; Moore, R. E.; Hirotsu, K.; Clardy, J., Majusculamides A and B, two epimeric 
lipodipeptides from Lyngbya majuscula. J Org Chem 1977, 42 (17), 2815-2819. 
FCUP 
A novel biocatalytic esterification involved in the biosynthesis of branched bartolosides 
57 
44. Nunnery, J. K.; Mevers, E.; Gerwick, W. H., Biologically active secondary metabolites from 
marine cyanobacteria. Curr Opin Biotechnol 2010, 21 (6), 787-93. 
45. Mynderse, J. S.; Moore, R. E., Toxins from blue-green algae: structures of oscillatoxin A 
and three related bromine-containing toxins. J Org Chem 1978, 43 (11), 2301-2303. 
46. Mynderse, J. S.; Moore, R. E.; Kashiwagi, M.; Norton, T. R., Antileukemia activity in the 
Osillatoriaceae: isolation of Debromoaplysiatoxin from Lyngbya. Science (New York) 1977, 196 
(4289), 538-40. 
47. Garcia-Pichel, F.; Sherry, N. D.; Castenholz, R. W., Evidence for an ultraviolet sunscreen 
role of the extracellular pigment scytonemin in the terrestrial cyanobacterium Chlorogloeopsis sp. 
Photochem Photobiol 1992, 56 (1), 17-23. 
48. Luesch, H.; Moore, R. E.; Paul, V. J.; Mooberry, S. L.; Corbett, T. H., Isolation of dolastatin 
10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and 
biological evaluation of its analogue symplostatin 1. J Nat Prod 2001, 64 (7), 907-10. 
49. Patel, S.; Keohan, M. L.; Saif, M. W.; Rushing, D.; Baez, L.; Feit, K.; DeJager, R.; 
Anderson, S., Phase II study of intravenous TZT-1027 in patients with advanced or metastatic 
soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer 2006, 107 
(12), 2881-7. 
50. Newman, D. J.; Cragg, G. M., Current Status of Marine-Derived Compounds as Warheads 
in Anti-Tumor Drug Candidates. Mar Drugs 2017, 15 (4), 99. 
51. Shah, S. A. A.; Akhter, N.; Auckloo, B. N.; Khan, I.; Lu, Y.; Wang, K.; Wu, B.; Guo, Y. W., 
Structural Diversity, Biological Properties and Applications of Natural Products from 
Cyanobacteria. A Review. Mar Drugs 2017, 15 (11). 
52. Pfannenstiel, B. T.; Keller, N. P., On top of biosynthetic gene clusters: How epigenetic 
machinery influences secondary metabolism in fungi. Biotechnol Adv 2019, 37 (6), 107345. 
53. Medema, M. H.; Kottmann, R.; Yilmaz, P.; Cummings, M.; Biggins, J. B.; Blin, K.; de Bruijn, 
I.; Chooi, Y. H.; Claesen, J.; Coates, R. C.; Cruz-Morales, P.; Duddela, S.; Düsterhus, S.; 
Edwards, D. J.; Fewer, D. P.; Garg, N.; Geiger, C.; Gomez-Escribano, J. P.; Greule, A.; 
Hadjithomas, M.; Haines, A. S.; Helfrich, E. J. N.; Hillwig, M. L.; Ishida, K.; Jones, A. C.; Jones, C. 
S.; Jungmann, K.; Kegler, C.; Kim, H. U.; Kötter, P.; Krug, D.; Masschelein, J.; Melnik, A. V.; 
Mantovani, S. M.; Monroe, E. A.; Moore, M.; Moss, N.; Nützmann, H.-W.; Pan, G.; Pati, A.; Petras, 
D.; Reen, F. J.; Rosconi, F.; Rui, Z.; Tian, Z.; Tobias, N. J.; Tsunematsu, Y.; Wiemann, P.; Wyckoff, 
E.; Yan, X.; Yim, G.; Yu, F.; Xie, Y.; Aigle, B.; Apel, A. K.; Balibar, C. J.; Balskus, E. P.; Barona-
Gómez, F.; Bechthold, A.; Bode, H. B.; Borriss, R.; Brady, S. F.; Brakhage, A. A.; Caffrey, P.; 
Cheng, Y.-Q.; Clardy, J.; Cox, R. J.; De Mot, R.; Donadio, S.; Donia, M. S.; van der Donk, W. A.; 
Dorrestein, P. C.; Doyle, S.; Driessen, A. J. M.; Ehling-Schulz, M.; Entian, K.-D.; Fischbach, M. 
A.; Gerwick, L.; Gerwick, W. H.; Gross, H.; Gust, B.; Hertweck, C.; Höfte, M.; Jensen, S. E.; Ju, 
J.; Katz, L.; Kaysser, L.; Klassen, J. L.; Keller, N. P.; Kormanec, J.; Kuipers, O. P.; Kuzuyama, T.; 
Kyrpides, N. C.; Kwon, H.-J.; Lautru, S.; Lavigne, R.; Lee, C. Y.; Linquan, B.; Liu, X.; Liu, W.; 
Luzhetskyy, A.; Mahmud, T.; Mast, Y.; Méndez, C.; Metsä-Ketelä, M.; Micklefield, J.; Mitchell, D. 
A.; Moore, B. S.; Moreira, L. M.; Müller, R.; Neilan, B. A.; Nett, M.; Nielsen, J.; O'Gara, F.; Oikawa, 
H.; Osbourn, A.; Osburne, M. S.; Ostash, B.; Payne, S. M.; Pernodet, J.-L.; Petricek, M.; Piel, J.; 
Ploux, O.; Raaijmakers, J. M.; Salas, J. A.; Schmitt, E. K.; Scott, B.; Seipke, R. F.; Shen, B.; 
Sherman, D. H.; Sivonen, K.; Smanski, M. J.; Sosio, M.; Stegmann, E.; Süssmuth, R. D.; Tahlan, 
K.; Thomas, C. M.; Tang, Y.; Truman, A. W.; Viaud, M.; Walton, J. D.; Walsh, C. T.; Weber, T.; 
van Wezel, G. P.; Wilkinson, B.; Willey, J. M.; Wohlleben, W.; Wright, G. D.; Ziemert, N.; Zhang, 
C.; Zotchev, S. B.; Breitling, R.; Takano, E.; Glöckner, F. O., Minimum Information about a 
Biosynthetic Gene cluster. Nat Chem Biol 2015, 11 (9), 625-631. 
54. Walsh, C. T.; Fischbach, M. A., Natural products version 2.0: connecting genes to 
molecules. J Am Chem Soc 2010, 132 (8), 2469-2493. 
FCUP 
A novel biocatalytic esterification involved in the biosynthesis of branched bartolosides 
58 
55. Jones, A. C.; Monroe, E. A.; Eisman, E. B.; Gerwick, L.; Sherman, D. H.; Gerwick, W. H., 
The unique mechanistic transformations involved in the biosynthesis of modular natural products 
from marine cyanobacteria. Nat Prod Rep 2010, 27 (7), 1048-65. 
56. Tidgewell, K.; Clark, B.; Gerwick, W., 2.06. The Natural Products Chemistry of 
Cyanobacteria. Comprehensive Natural Products II 2010, 2. 
57. Finking, R.; Marahiel, M. A., Biosynthesis of Nonribosomal Peptides. Annu Rev Microbiol 
2004, 58 (1), 453-488. 
58. Yang, X.; van der Donk, W. A., Ribosomally synthesized and post-translationally modified 
peptide natural products: new insights into the role of leader and core peptides during 
biosynthesis. Chemistry 2013, 19 (24), 7662-7677. 
59. Martins, J.; Leikoski, N.; Wahlsten, M.; Azevedo, J.; Antunes, J.; Jokela, J.; Sivonen, K.; 
Vasconcelos, V.; Fewer, D. P.; Leão, P. N., Sphaerocyclamide, a prenylated cyanobactin from the 
cyanobacterium Sphaerospermopsis sp. LEGE 00249. Sci Rep-UK 2018, 8 (1), 14537. 
60. Shen, B., Polyketide biosynthesis beyond the type I, II and III polyketide synthase 
paradigms. Curr Opin Chem Biol 2003, 7 (2), 285-95. 
61. Staunton, J.; Weissman, K. J., Polyketide biosynthesis: a millennium review. Nat Prod Rep 
2001, 18 (4), 380-416. 
62. Hamley, I. W., Lipopeptides: from self-assembly to bioactivity. Cheml Commun 2015, 51 
(41), 8574-8583. 
63. Katz, L.; Baltz, R. H., Natural product discovery: past, present, and future. J Ind Microbiol 
Biotechnol 2016, 43 (2-3), 155-76. 
64. Chaguturu, R.; Patwardhan, B., Chapter 1 - Drug Discovery Impasse: Pharmacognosy 
Holds the Key. In Innovative Approaches in Drug Discovery Eds. Academic Press: Boston, 2017; 
pp 1-22. 
65. Cronk, D., Chapter 8 - High-throughput screening. In Drug Discovery and Development 
(Second Edition) Eds. Churchill Livingstone: 2013; pp 95-117. 
66. Griffiths, J., A Brief History of Mass Spectrometry. Anal Chem 2008, 80 (15), 5678-5683. 
67. Kildgaard, S.; Subko, K.; Phillips, E.; Goidts, V.; de la Cruz, M.; Diaz, C.; Gotfredsen, C. 
H.; Andersen, B.; Frisvad, J. C.; Nielsen, K. F.; Larsen, T. O., A Dereplication and Bioguided 
Discovery Approach to Reveal New Compounds from a Marine-Derived Fungus Stilbella fimetaria. 
Mar Drugs 2017, 15 (8). 
68. Heather, J. M.; Chain, B., The sequence of sequencers: The history of sequencing DNA. 
Genomics 2016, 107 (1), 1-8. 
69. Niu, G., Genomics-Driven Natural Product Discovery in Actinomycetes. Trends Biotechnol 
2018, 36 (3), 238-241. 
70. Challis, G. L., Genome Mining for Novel Natural Product Discovery. J Med Chem 2008, 51 
(9), 2618-2628. 
71. Chen, R.; Wong, H. L.; Burns, B. P., New Approaches to Detect Biosynthetic Gene 
Clusters in the Environment. Medicines (Basel) 2019, 6 (1), 32. 
72. Rodríguez Estévez, M.; Myronovskyi, M.; Gummerlich, N.; Nadmid, S.; Luzhetskyy, A., 
Heterologous Expression of the Nybomycin Gene Cluster from the Marine Strain Streptomyces 
albus subsp. chlorinus NRRL B-24108. Mar Drugs 2018, 16 (11), 435. 
73. Micallef, M. L.; D'Agostino, P. M.; Al-Sinawi, B.; Neilan, B. A.; Moffitt, M. C., Exploring 
cyanobacterial genomes for natural product biosynthesis pathways. Mar Genom 2015, 21, 1-12. 
74. Dittmann, E.; Gugger, M.; Sivonen, K.; Fewer, D. P., Natural Product Biosynthetic Diversity 
and Comparative Genomics of the Cyanobacteria. Trends Microbiol 2015, 23 (10), 642-652. 
75. Sletten, E. M.; Bertozzi, C. R., Bioorthogonal chemistry: fishing for selectivity in a sea of 
functionality. Angew Chem Int Ed Engl 2009, 48 (38), 6974-6998. 
76. Kolb, H. C.; Finn, M. G.; Sharpless, K. B., Click Chemistry: Diverse Chemical Function 
from a Few Good Reactions. Angew Chem Int Ed Engl 2001, 40 (11), 2004-2021. 
FCUP 
A novel biocatalytic esterification involved in the biosynthesis of branched bartolosides 
59 
77. Kolb, H. C.; Sharpless, K. B., The growing impact of click chemistry on drug discovery. 
Drug Discov Today 2003, 8 (24), 1128-37. 
78. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B., A Stepwise Huisgen 
Cycloaddition Process: Copper(I)-Catalyzed Regioselective “Ligation” of Azides and Terminal 
Alkynes. Angew Chem Int Ed Engl 2002, 41 (14), 2596-2599. 
79. Speers, A. E.; Adam, G. C.; Cravatt, B. F., Activity-Based Protein Profiling in Vivo Using a 
Copper(I)-Catalyzed Azide-Alkyne [3 + 2] Cycloaddition. J Am Chem Soc 2003, 125 (16), 4686-
4687. 
80. Presolski, S. I.; Hong, V. P.; Finn, M. G., Copper-Catalyzed Azide-Alkyne Click Chemistry 
for Bioconjugation. Curr Protoc Chem Biol 2011, 3 (4), 153-162. 
81. Afonso, T. B.; Costa, M. S.; Rezende de Castro, R.; Freitas, S.; Silva, A.; Schneider, M. 
P.; Martins, R.; Leao, P. N., Bartolosides E-K from a Marine Coccoid Cyanobacterium. J Nat Prod 
2016, 79 (10), 2504-2513. 
82. Leao, P. N.; Nakamura, H.; Costa, M.; Pereira, A. R.; Martins, R.; Vasconcelos, V.; 
Gerwick, W. H.; Balskus, E. P., Biosynthesis-assisted structural elucidation of the bartolosides, 
chlorinated aromatic glycolipids from cyanobacteria. Angew Chem Int Ed Engl 2015, 54 (38), 
11063-7. 
83. Martins, T. P.; Rouger, C.; Glasser, N. R.; Freitas, S.; de Fraissinette, N. B.; Balskus, E. 
P.; Tasdemir, D.; Leao, P. N., Chemistry, bioactivity and biosynthesis of cyanobacterial 
alkylresorcinols. Nat Prod Rep 2019. 
84. Moore, B. S.; Chen, J. L.; Patterson, G. M. L.; Moore, R. E.; Brinen, L. S.; Kato, Y.; Clardy, 
J., [7.7]Paracyclophanes from blue-green algae. J Am Chem Soc 1990, 112 (10), 4061-4063. 
85. Beresovsky, D.; Hadas, O.; Livne, A.; Sukenik, A.; Kaplan, A.; Carmeli, S., Toxins and 
Biologically Active Secondary Metabolites of Microcystis sp. isolated from Lake Kinneret. Israel J 
Chem 2006, 46 (1), 79-87. 
86. Ploutno, A.; Carmeli, S., Nostocyclyne A, a Novel Antimicrobial Cyclophane from the 
Cyanobacterium Nostoc sp. J Nat Prod 2000, 63 (11), 1524-1526. 
87. Nakamura, H.; Hamer, H. A.; Sirasani, G.; Balskus, E. P., Cylindrocyclophane biosynthesis 
involves functionalization of an unactivated carbon center. J Am Chem Soc 2012, 134 (45), 18518-
21. 
88. Kleigrewe, K.; Almaliti, J.; Tian, I. Y.; Kinnel, R. B.; Korobeynikov, A.; Monroe, E. A.; 
Duggan, B. M.; Di Marzo, V.; Sherman, D. H.; Dorrestein, P. C.; Gerwick, L.; Gerwick, W. H., 
Combining Mass Spectrometric Metabolic Profiling with Genomic Analysis: A Powerful Approach 
for Discovering Natural Products from Cyanobacteria. J Nat Prod 2015, 78 (7), 1671-82. 
89. Nakamura, H.; Schultz, E. E.; Balskus, E. P., A new strategy for aromatic ring alkylation in 
cylindrocyclophane biosynthesis. Nat Chem Biol 2017, 13 (8), 916-921. 
90. Schultz, E. E.; Braffman, N. R.; Luescher, M. U.; Hager, H. H.; Balskus, E. P., Biocatalytic 
Friedel-Crafts Alkylation Using a Promiscuous Biosynthetic Enzyme. Angew Chem Int Ed Engl 
2019, 58 (10), 3151-3155. 
91. Agarwal, V.; Miles, Z. D.; Winter, J. M.; Eustaquio, A. S.; El Gamal, A. A.; Moore, B. S., 
Enzymatic Halogenation and Dehalogenation Reactions: Pervasive and Mechanistically Diverse. 
Chem Rev 2017, 117 (8), 5619-5674. 
92. Stalcup, A. M.; Martire, D. E.; Wise, S. A., Thermodynamic comparison of monomeric and 
polymeric C18 bonded phases using aqueous methanol and acetonitrile mobile phases. J 
Chromatogr A 1988, 442, 1-14. 
93. Fischer, E.; Speier, A., Darstellung der Ester. Berichte der deutschen chemischen 
Gesellschaft 1895, 28 (3), 3252-3258. 
94. Sharp, P. M.; Li, W. H., The codon Adaptation Index--a measure of directional synonymous 
codon usage bias, and its potential applications. Nucleic Acids Res 1987, 15 (3), 1281-1295. 
FCUP 
A novel biocatalytic esterification involved in the biosynthesis of branched bartolosides 
60 
95. Schmidt, T. G. M.; Skerra, A., The Strep-tag system for one-step purification and high-
affinity detection or capturing of proteins. Nat Protoc 2007, 2, 1528. 
96. Kibbe, W. A., OligoCalc: an online oligonucleotide properties calculator. Nucleic Acids Res 
2007, 35 (Web Server issue), W43-W46. 
97. Otera, J.; Nishikido, J., Conversion of Carboxylic Acids into Esters without Use of Alcohols. 
Esterification: Methods, Reactions and Applications (second edition) 2010; pp 173-192. 
98. Haslam, E., Recent developments in methods for the esterification and protection of the 
carboxyl group. Tetrahedron 1980, 36 (17), 2409-2433. 
99. Fischbach, M. A.; Walsh, C. T., Assembly-line enzymology for polyketide and 
nonribosomal Peptide antibiotics: logic, machinery, and mechanisms. Chem Rev 2006, 106 (8), 
3468-96. 
100. Arora, P.; Goyal, A.; Natarajan, V. T.; Rajakumara, E.; Verma, P.; Gupta, R.; Yousuf, M.; 
Trivedi, O. A.; Mohanty, D.; Tyagi, A.; Sankaranarayanan, R.; Gokhale, R. S., Mechanistic and 
functional insights into fatty acid activation in Mycobacterium tuberculosis. Nat Chem Biol 2009, 5 
(3), 166-173. 
101. Lortie, R., Esterification ‐ Biological. In Encyclopedia of Catalysis I Horváth (Ed.) 2010. 
102. LaMattina, J. W.; Wang, B.; Badding, E. D.; Gadsby, L. K.; Grove, T. L.; Booker, S. J., 
NosN, a Radical S-Adenosylmethionine Methylase, Catalyzes Both C1 Transfer and Formation of 
the Ester Linkage of the Side-Ring System during the Biosynthesis of Nosiheptide. J Am Chem 
Soc 2017, 139 (48), 17438-17445. 
103. O'Hagan, D.; Schmidberger, J. W., Enzymes that catalyse SN2 reaction mechanisms. Nat 
Prod Rep 2010, 27 (6), 900-918. 
104. Liu, J. Q.; Kurihara, T.; Hasan, A. K.; Nardi-Dei, V.; Koshikawa, H.; Esaki, N.; Soda, K., 
Purification and characterization of thermostable and nonthermostable 2-haloacid dehalogenases 
with different stereospecificities from Pseudomonas sp. strain YL. Appl Environ Microb 1994, 60 
(7), 2389-93. 
105. Liu, J. Q.; Kurihara, T.; Miyagi, M.; Esaki, N.; Soda, K., Reaction mechanism of L-2-
haloacid dehalogenase of Pseudomonas sp. YL. Identification of Asp10 as the active site 
nucleophile by 18O incorporation experiments. J Biol Chem 1995, 270 (31), 18309-12. 
106. Ramos, V.; Morais, J.; Castelo-Branco, R.; Pinheiro, Â.; Martins, J.; Regueiras, A.; Pereira, 
A. L.; Lopes, V. R.; Frazão, B.; Gomes, D.; Moreira, C.; Costa, M. S.; Brûle, S.; Faustino, S.; 
Martins, R.; Saker, M.; Osswald, J.; Leão, P. N.; Vasconcelos, V. M., Cyanobacterial diversity held 
in microbial biological resource centers as a biotechnological asset: the case study of the newly 
established LEGE culture collection. J Appl Phycol 2018, 30 (3), 1437-1451. 
FCUP 
A novel biocatalytic esterification involved in the biosynthesis of branched bartolosides 
61 
VI. Annexes 
Annex Text 1 – Protein and DNA sequences 
Protein Sequence (NStrep-BrtB, 91.4 kDa) 
MASWSHPQFEKGADDDDKVPDPTSVDMANPFDVALTNLNSLYSGIPDVPVLQTYNSLNPYDISLTNLNNLSNFVIEPA
VLPTAAGTYGPQISEIAFALGGGIITGALADLLSTELGIEIENEALITKFLSFWTPGSDYAFGQDYVEFIQGREGFDT
IIGYDPGFNSALAPVQIDFVLGGPRQDFNFFAPLDEPARYVLGDWRTPYYVDNDIQSEGLNEFMYVSLFTLNPDEFSP
DNAENHRIQLYGSLDNYYFVPTTVVIDGSALDPSLPSIPVPGTEIYYKTGQVFADLIAIVPFQDPNDPNLISAWIDFE
GYLPPEQADLSGQTANPLLSGSPLLQLGYEGIDMGTATALAPDGDIYVAGSTSSLLGPFPRGGSDNFIARYNDDGSLE
WIVQFGSTEFDIITDIVSDSAGNVYATGWTRGNVETGFGLAPGVQDNWVAKFDANGSQLWVEQFTIDGYLDRSMGIAL
DEVNGRIHLTGHSNTDGSVADTNDPAIVPNGNVVTWIAGFDANTGAEDYRNVFEVAQTSNSRGRIDEGFGIDVDDAGN
VFSTGWAGENAYDVYLVKSDTDGAVLWTKSFGTGSNATQSYAWDVASDGTNAYILGWTQGELNTFRDQIPPTDEFAGN
ATAPLTPQNAYQGGTFDAFVAAYDTDGTELWTWHVGGTGDDGTFFGKIVAAGDFVYATGYTDGFIGTLGGSNAGDYDA
WIGKFDKLTGQTAWIQQIGSTKLDYATGISVDGDDIFVTGFTEGSLGGLNGGASDAWVAKLNQDGALEAFNVSAPIAP
PAPFAPPAPLTPPAPPAPDLSSLQSLGSTPQPTYPALGDSYGTNPFGTQPTQPTYDLSSMYQNAYYGGFGGYSGYGY 
DNA sequence (NStrep-brtB) 
ATGGCAAGCTGGAGCCACCCGCAGTTCGAAAAGGGTGCAGATGACGACGACAAGGTACCGGATCCGACGTCGGTCGAC
ATGGCCAATCCCTTCGACGTCGCTTTAACTAATCTTAACAGTCTTTACAGCGGTATCCCTGATGTTCCCGTTCTTCAG
ACGTACAACTCTCTTAACCCCTACGACATTTCTTTAACTAATCTTAACAATCTTAGCAACTTCGTCATTGAGCCAGCC
GTGCTCCCTACAGCGGCAGGTACCTACGGCCCTCAAATCAGTGAAATTGCTTTTGCGTTGGGGGGTGGGATCATAACA
GGGGCACTAGCTGATCTGCTATCCACTGAGTTGGGGATCGAGATCGAGAACGAAGCTCTGATAACTAAGTTCCTTTCC
TTCTGGACTCCCGGTTCCGATTACGCCTTCGGTCAGGATTATGTTGAATTTATTCAAGGTCGGGAAGGCTTTGACACC
ATCATCGGTTACGACCCCGGATTCAACAGTGCATTAGCTCCCGTACAAATTGACTTTGTCCTTGGCGGCCCCAGGCAG
GACTTTAACTTCTTTGCCCCCTTAGATGAGCCAGCACGCTACGTTTTGGGTGATTGGCGGACCCCCTATTATGTGGAT
AACGATATCCAGAGTGAGGGGCTGAACGAGTTTATGTATGTTTCGCTCTTCACACTTAACCCGGATGAATTTTCGCCA
GACAATGCAGAAAATCATCGTATCCAGCTCTACGGCAGTCTGGACAATTACTACTTTGTACCAACGACAGTTGTAATT
GATGGAAGCGCCCTAGATCCAAGTCTTCCATCAATTCCCGTCCCAGGCACAGAAATTTACTATAAAACCGGGCAGGTT
TTTGCAGATCTGATTGCCATTGTGCCTTTCCAGGATCCTAACGACCCAAATCTTATTTCCGCCTGGATTGATTTTGAG
GGCTATCTGCCCCCGGAACAGGCCGACCTGAGTGGCCAGACCGCGAACCCCTTGCTCTCCGGTTCTCCCCTCCTTCAA
TTGGGCTACGAAGGCATCGATATGGGTACGGCAACGGCCCTCGCCCCGGATGGTGATATCTACGTCGCTGGCTCCACT
AGCAGTCTTTTGGGACCTTTTCCCCGTGGAGGTTCAGACAACTTCATCGCCCGCTACAACGACGATGGTAGCTTGGAA
TGGATTGTTCAATTTGGTAGCACTGAGTTCGACATAATCACCGACATTGTCAGCGACAGCGCTGGTAACGTTTATGCC
ACCGGTTGGACCCGGGGCAATGTGGAGACGGGTTTTGGCCTGGCCCCAGGTGTTCAAGACAATTGGGTAGCCAAATTT
GATGCCAATGGCAGCCAACTCTGGGTAGAGCAATTTACCATTGATGGCTACCTCGACCGTTCCATGGGCATTGCCCTC
GATGAAGTCAATGGGAGAATTCACCTGACAGGGCACTCCAACACGGATGGCTCCGTTGCGGATACAAACGACCCCGCC
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ATTGTCCCCAATGGTAATGTGGTCACCTGGATTGCTGGTTTTGATGCTAACACTGGAGCAGAAGACTATCGCAATGTC
TTTGAAGTCGCCCAAACCTCTAACAGCCGGGGACGCATTGATGAAGGTTTTGGCATAGATGTTGACGATGCTGGCAAT
GTGTTCTCCACCGGTTGGGCCGGAGAAAACGCCTACGACGTCTATCTGGTTAAATCCGATACGGATGGCGCTGTACTC
TGGACCAAGAGCTTCGGAACTGGGTCTAATGCCACCCAAAGTTATGCCTGGGATGTTGCTAGTGATGGCACCAATGCC
TATATCCTAGGTTGGACCCAGGGCGAACTCAACACATTCCGCGATCAAATTCCTCCCACGGATGAATTTGCGGGTAAT
GCGACGGCTCCACTTACTCCGCAAAATGCTTACCAAGGTGGTACCTTCGATGCCTTTGTTGCCGCCTATGACACCGAT
GGTACTGAACTCTGGACTTGGCATGTAGGTGGAACAGGGGATGATGGAACCTTCTTCGGTAAAATTGTCGCTGCTGGG
GACTTTGTTTACGCCACAGGCTATACCGATGGCTTTATTGGCACCCTAGGTGGCAGTAACGCTGGTGACTACGATGCC
TGGATCGGTAAGTTTGATAAGTTAACCGGTCAGACTGCATGGATCCAGCAGATTGGTAGCACCAAGCTAGACTACGCC
ACTGGTATTTCCGTTGATGGCGATGACATTTTCGTAACAGGCTTTACGGAAGGTTCCTTGGGCGGCTTGAACGGTGGT
GCTTCCGACGCCTGGGTTGCTAAGTTAAATCAAGATGGCGCTTTAGAAGCTTTTAATGTTTCTGCCCCTATTGCTCCC
CCAGCTCCTTTTGCTCCCCCAGCCCCTCTTACTCCTCCAGCTCCCCCGGCTCCTGATCTCAGTAGCTTGCAGTCATTG
GGTAGCACCCCTCAGCCGACCTACCCGGCCCTTGGGGACAGCTATGGCACTAACCCCTTTGGTACTCAGCCTACTCAA
CCTACCTATGACCTCAGCAGCATGTACCAAAATGCTTACTATGGCGGCTTCGGAGGTTATTCCGGGTACGGCTACTAG 
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Annex Figure 1. Detection and HRESIMS/MS based structural assignment of naturally occurring bartoloside A esters produced by 
S. salina LEGE06099. a) Annotated MS/MS fragments for the structures of bartoloside A and G esters. b-i) Extracted Ion 
Chromatograms (EICs) for the [M-H+HCOOH]- ion and MS/MS spectra for the [M-H]- specie of some of the detected naturally occurring 
bartoloside A esters.  
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Annex Figure 2. Detection and HRESIMS/MS based structural assignment of naturally occurring bartoloside G esters produced by 
S. salina LEGE06099. a) Annotated MS/MS fragments for the structures of bartoloside A and G esters. b-d) Extracted Ion 
Chromatograms (EICs) for the [M-H+HCOOH]- ion and MS/MS spectra for the [M-H]- specie of some of the detected naturally 
occurring bartoloside G esters. 
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Annex Figure 3. 1H NMR spectra for subfraction 15.7 obtained during the isolation of bartoloside A monopalmitate.
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Annex Figure 4. HRESIMS/MS of fraction 15.7.2 obtained during the isolation of compound 5a with respective structural 
assignment (top).  
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Annex Figure 5. LC-HRESIMS/MS analysis of the bartoloside esters 3 and 8a/8b (a) and 5a (b) formed in the full assay. It was not 
possible to fragment the diester 7due to low abundance of the precursor ion.  
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Annex Table 1. NMR Spectroscopic Data (1H 400 MHz, 13C 100 MHz, CDCl3) for bartoloside A-17,29-diyl bis(hept-6yonate) (3). 
 
 
 
 
afrom HSQC; bfrom proton to indicated carbon. 
position δc type δHa mult, J (Hz) HMBCb COSY 
1 155.8 C     
2 116.3 C     
3 154.6 C-OH     
4 110.4 CH 6.36 d, 1.4 154.6, 116.3, 107.8, 35.6 6.47, 2.48 
5 141.9 C     
6 107.8 CH 6.47 d, 1.4 155.8, 116.3, 110.4, 35.6 6.36, 2.48 
7 101.4 CH 4.99 d, 5.6 155.8, 74.9, 64.5 3.71, 3.70 
8 72.6 CH-OH 3.71 m 101.4, 74.9 4.99, 3.80 
9 74.9 CH-OH 3.70 m 72.6, 69.7 4.99, 3.80 
10 69.7 CH-OH 3.80 m 74.9 4.10, 3.71, 3.70, 3.45 
11 64.5 CH2 4.10/3.45 dd, 11.9, 4.4/12.0, 8.2 101.4, 74.9, 69.7 3.80, 3.45/4.10, 3.80 
12 23.3 CH2 2.58 t, 7.8 155.8, 154.6, 116.3, 29.3 1.51-1.49, 1.50 
13 29.3 CH2 1.50 m  2.58 
14, 20, 26, 32, 33 29.6-29.0 5 × CH2 1.32-1.28 m 31.9, 31.8, 29.6-29.0, 14.2, 14.1 1.51-1.49, 0.87 
15a, 19a, 27a, 31a 25.4-25.1 4 × CH2 1.51-1.49 m 74.8, 74-6, 31.9, 31.8, 29.6-29.0 4.87, 2.58, 1.32-1.28, 1.27-1.24 
15b, 19b, 27b, 31b   1.27-1.24 m 31.9, 31.8, 29.6-29.0 1.51-1.49 
16a, 18a, 28a, 30a 34.3-34.1 4 × CH2 1.51-1.49 m 74.8, 74.6, 31.9, 31.8, 29.6-29.0, 25.4-25.1 4.87, 1.32-1.28, 1.27-1.24 
16b, 18b, 28b, 30b   1.27-1.24 m 29.6-29.0, 25.4-25.1 1.51-1.49 
17/29 74.8/74.6 2 × CH 4.87 m 174.1, 173.9, 34.3-34.1, 25.4-25.1 1.51-1.49 
21/34 31.9/31.8 2 × CH2 1.27-1.24 m 29.6-29.0, 25.4-25.1, 14.2, 14.1 1.51-1.49, 0.87 
22/35 22.7 2 × CH2 1.27-1.24 m 31.9, 31.8, 29.6-29.0, 25.4-25.1, 14.2, 14.1 1.51-1.49, 0.87 
23/36 14.2/14.1 2 × CH3 0.87 m 31.9, 31.8, 22.7 1.32-1.28, 1.27-1.24 
24 35.6 CH2 2.48 t, 7.5 141.9, 110.4, 107.8, 34.3-34.1, 30.9, 29.6-29.0 6.47, 6.36, 1.55 
25 30.9 CH2 1.55 m 141.9, 29.6-29.0 2.48 
1'/ 1'' 174.1/173.9 2 × C     
2'/ 2'' 34.3/34.3 2 × CH2 2.32 dt, 7.4, 2.2 174.1, 173.9, 28.0, 24.3 1.73 
3'/3'' 24.3 2 × CH2 1.73 m 174.1, 173.9, 34.3, 28.0, 18.3, 18.2 2.32, 1.55 
4'/ 4'' 28.0 2 × CH2 1.55 m 84.1, 34.3, 24.3, 18.3, 18.2 2.20, 1.73 
5'/ 5'' 18.3/18.2 2 × CH2 2.20 tt, 7.0, 2.7 84.1, 68.8, 28.0, 24.3 1.95, 1.55 
6'/ 6'' 84.1 2 × C     
7'/ 7'' 68.8 2 × CH 1.95 m 84.1, 18.2, 18.3 2.20 
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Annex Figure 6. 1H NMR (CDCl3, 400 MHz) spectrum of compound 3. 
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Annex Figure 7. 13C NMR (CDCl3, 100 MHz) spectrum of compound 3. 
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Annex Figure 8. HSQC (CDCl3, 400 MHz) spectrum of compound 3. 
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Annex Figure 9. HMBC (CDCl3, 400 MHz) spectrum of compound 3. 
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Annex Figure 10. COSY (CDCl3, 400 MHz) spectrum of compound 3. 
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Annex Table 2. NMR Spectroscopic Data (1H 400 MHz, 13C 100 MHz, CDCl3) for bartoloside G-17-yl hept-6-ynoate (4) 
 
 
 
 
 
afrom HSQC; bfrom proton to indicated carbon. 
position δc  type δHa mult, J (Hz) HMBCb COSY 
1 155.7  C     
2 116.1  C     
3 154.3  C-OH     
4 110.4  CH 6.36 d, 1.5 154.3, 116.1, 108.1, 36.0 6.51, 2,49 
5 142.5  C     
6 108.1  CH 6.51 d, 1.5 155.7, 116.1, 110.4, 36.0 6.36, 2.49 
7 101.4  CH 5.00 d, 5.7 155.7, 74.9, 64.5 3.72, 3.70 
8 72.6  CH-OH 3.72 m  5.00, 3.83 
9 74.9  CH-OH 3.70 m  5.00, 3.83 
10 69.7  CH-OH 3.83 m  4.12, 3.72, 3.70, 3.47 
11 64.5  CH2 4.12/3.47 dd, 11.9, 4.4/11.9, 8.1 101.4, 74.9/101.4, 74.9, 69.7 3.83, 3.47/4.12, 3.83 
12 23.3  CH2 2.58 t, 7.8 155.7, 154.3, 116.1, 29.1 1.51-1.50, 1.50 
13 29.1  CH2 1.50 m  2.58 
14/20, 26-33 29.9-29.0  10 × CH2 1.27-1.24 m 32.1, 31.8, 29.9-29.0, 22.8, 22.7, 14.3, 14.2 1.51-1.50, 0.87 
15a, 19a 25.3/25.2  2 × CH2 1.51-1.50 m 32.1, 31.8 4.88, 2.58, 1.30-1.28 
15b, 19b    1.30-1.28 m 32.1, 31.8, 29.9-29.5 1.51-1.50 
16a, 18a 34.3  2 × CH2 1.51-1.50 m 32.1, 31.8, 25.3, 25.2 4.88, 1.30-1.28, 1.27-1.24 
16b, 18b    1.27-1.24 m 29.9-29.0 1.51-1.50 
17 74.7  CH 4.88 p, 6.2 174.1, 34.3, 25.3, 25.2 1.51-1.50 
21/34 32.1/31.8  2 × CH2 1.27-1.24 m 29.9-29.0, 22.8, 22.7, 14.3, 14.2 1.51-1.50, 0.87 
22/35 22.8/22.7  2 × CH2 1.27-1.24 m 32.1, 31.8, 29.85-29.51, 14.3, 14.2 1.51-1.50, 0.87 
23/36 14.3/14.2  2 × CH3 0.87 m 32.1, 31.8, 22.8, 22.7 1.30-1.28, 1.27-1.24 
24 36.0  CH2 2.49 t, 7.7 142.5, 110.4, 108.1, 31.4, 29.9-29.0 6.51, 6.36, 1.56 
25 31.4  CH2 1.56 m 29.9-29.0 2.49 
1' 174.1  C     
2' 34.4  CH2 2.32 t, 7.4 174.1, 28.0, 24.3 1.74 
3' 24.3  CH2 1.74 m 174.1, 34.4, 28.0, 18.3 2.32, 1.55 
4' 28.0  CH2 1.55 m 84.1, 34.4, 24.3, 18.3 2.20, 1.74 
5' 18.3  CH2 2.20 td, 7.0, 2.6 84.1, 68.8, 28.0, 24.3 1.95, 1.55 
6' 84.1  C     
7' 68.8  CH 1.95 t, 2.7  2.20 
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Annex Figure 11. 1H NMR (CDCl3, 400 MHz) spectrum of compound 4. 
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Annex Figure 12. 13C NMR (APT, CDCl3, 100 MHz) spectrum of compound 4. 
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Annex Figure 13. HSQC (CDCl3, 400 MHz) spectrum of compound 4. 
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Annex Figure 14. HMBC (CDCl3, 400 MHz) spectrum of compound 4. 
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Annex Figure 15. COSY (CDCl3, 400 MHz) spectrum of compound 4.
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Annex Table 3. NMR Spectroscopic Data (1H 400 MHz, 13C 100 MHz, CDCl3) for bartoloside A-17-yl palmitate (5a) 
 
 
 
afrom HSQC; bfrom proton to indicated carbon. 
position δc type δHa mult, J (Hz) HMBCb COSY 
1 155.8 C     
2 116.2 C     
3 154.3 C-OH     
4 110.4 CH 6.36 s 154.3, 116.2, 108.1, 35.9 6.51 
5 142.3 C     
6 108.1 CH 6.51 s 155.8, 116.2, 110.4, 35.9 6.36 
7 101.4 CH 5.01 d, 5.7 155.8 3.72, 3.70 
8 72.6 CH-OH 3.72 m 101.4, 74.9 5.01, 3.83 
9 74.9 CH-OH 3.70 m 72.6, 69.8 5.01, 3.83 
10 69.8 CH-OH 3.83 m  4.13, 3.72, 3.70, 3.48 
11 64.6 CH2 4.13/3.48 dd, 11.9, 4.4/dd, 11.9, 8.0 101.4, 74.9/101.4, 69.8 3.83, 3.48/4.13, 3.83 
12 23.2 CH2 2.58 t, 7.7 155.8, 154.3, 116.2, 29.2 1.51, 1.51-1.50 
13 29.2 CH2 1.51 m  2.58 
14, 20, 26, 32, 33, 4'-13' 29.9-28.9 15 × CH2 1.27-1.24 m 29.9-28.9, 22.8-22.7 1.51-1.50, 0.88 
15a, 19a 25.2 2 × CH2 1.61-1.60  29.9-28.9 2.28, 1.30-1.28 
15b, 19b   1.30-1.28  32.1-31.9, 29.9-28.9, 22.8-22.7 1.61-1.60, 1.51-1.50 
16a, 18a 34.3 2 × CH2 1.51-1.50 m  4.88, 1.30-1.28, 1.41-1.40 
16b, 18b   1.27-1.24 m 29.9-28.9 1.51-1.50 
17 74.5 CH 4.88 p, 6.4 174.7, 25.2 1.51-1.50 
21, 34, 14' 32.1-31.9 3 × CH2 1.27-1.24 m 29.9-28.9, 22.8-22.7 1.51-1.50, 0.88 
22, 35, 15' 22.8-22.7 3 × CH2 1.30-1.28 m 32.1-31.9, 29.9-28.9, 22.8-22.7 1.61-1.60, 0.88 
23, 36, 16' 14.3-14.2 3 × CH3 0.88 m 32.1-31.9, 22.8-22.7 1.30-1.28 
24 35.9 CH2 2.5 t, 7.7 142.3, 110.4, 108.1, 31.2 1.58 
25 31.2 CH2 1.58 m  2.5 
27a, 31a 26.6 2 × CH2 1.51-1.50 m  1.7, 1.41-1.40 
27b, 31b   1.41-1.40 m  1.51-1.50 
28/30 38.7 2 × CH2 1.70 m 64.5 3.88, 1.51-1.50 
29 64.5 CH-Cl 3.88 m 26.6 1.70 
1' 174.7 C     
2' 35.0 CH2 2.28 t, 7.5 174.7, 29.9-28.9, 25.3 1.61-1.60 
3' 25.3 CH2 1.61-1.60 m 29.9-28.9 2.28 
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Annex Figure 16. 1H NMR (CDCl3, 400 MHz) spectrum of compound 5a. 
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Annex Figure 17. 13C NMR (APT, CDCl3, 100 MHz) spectrum of compound 5a. 
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Annex Figure 18. HSQC (CDCl3, 400 MHz) spectrum of compound 5a. 
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Annex Figure 19. HMBC (CDCl3, 400 MHz) spectrum of compound 5a 
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Annex Figure 20. COSY (CDCl3, 400 MHz) spectrum of compound 5a
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